KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
KOL简历 Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima：影响统计
运行报告
| Concept | World rank |
|---|---|
| levocabastine artificial tears | #1 |
| conjunctivitis concomitantly | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| bak epithelium | #1 |
| higher capilia | #1 |
| objective findings conclusions | #1 |
| fml patients | #1 |
| sodium allergic | #1 |
| adenovirus capilia | #1 |
| akc administration | #1 |
| immunocytochemical study rtpcr | #1 |
| fumarate dexamethasone | #1 |
| adeno eye | #1 |
| conjunctivitis aims | #1 |
| 12 patients akc | #1 |
| eye surface years | #1 |
| tacrolimus ophthalmic solution | #1 |
| drop levocabastine | #1 |
| fluorometholone 002 | #1 |
| efficacy fml | #1 |
| child conjunctivitis | #1 |
| conjunctivitis seasonal | #1 |
| tacrolimus ophthalmic suspension | #1 |
| 0001 allerwatch | #1 |
| initiation tacrolimus treatment | #1 |
| artificial tears positive | #1 |
| conjunctivitis japanese | #1 |
| severe akc | #1 |
| allerwatch higher | #1 |
| clinical signs akc | #1 |
| solution ocular | #1 |
| keratoconjunctivitis akc | #1 |
| release inhibitor purpose | #1 |
| patients allergic conjunctivitis | #1 |
| adverse events scores | #1 |
| hundredandseventy eyes | #1 |
| il4 tranilast | #1 |
| allergic conjunctivitis | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| eyewash | #1 |
| dha il4 | #1 |
| eye fml | #1 |
| scores hyperemia | #1 |
| commercial eyewash | #1 |
| conjunctivitis helper | #1 |
| test capilia | #1 |
| epithelium disorders | #1 |
| dha western blotting | #1 |
| include conjunctival | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| keratoconjunctivitis vernal | #1 |
| tacrolimus eye | #1 |
| samples allergic conjunctivitis | #1 |
| suspension treating | #1 |
| conjunctivitis enrolled | #1 |
| keratocytes tnfα | #1 |
| akc treatment | #1 |
| suppressing pge2 production | #1 |
| concomitant bf | #1 |
| selective chemotactic effects | #1 |
| eyebon | #1 |
| cox2 conjunctival | #1 |
| akc allergic | #1 |
| conclusions objective assessments | #1 |
| dscg fml | #1 |
| ded anti | #1 |
| efficacy bromfenac sodium | #1 |
| nsaids systemic control | #1 |
| cases severe conjunctivitis | #1 |
| ige allerwatch | #1 |
| severity objective signs | #1 |
| capilia adeno | #1 |
| initiating tacrolimus | #1 |
| keratoconjunctivitis male | #1 |
| eye wash | #1 |
| corneal epithelium disorders | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| pcr eotaxin1 | #1 |
| conjunctivitis conjunctival | #1 |
| akc vkc | #1 |
| tacrolimus tears | #1 |
| tacrolimus eye treatment | #1 |
| characterized conjunctival | #1 |
| tears allergic | #1 |
| allergic docosahexaenoic | #1 |
| vkc april | #1 |
| higher akc | #1 |
| ocular allergic diseases | #1 |
| sodium bf | #1 |
| akc vernal | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| itchy sensation | #1 |
| vkc conclusions | #1 |
| 3 months signs | #1 |
| allergens levocabastine | #1 |
| bromobenzenes conjunctivitis | #1 |
| allergic tranilast | #1 |
| akc methods | #1 |
| production tranilast | #1 |
| patients akc | #1 |
| conjunctivitis including | #1 |
| incubated interleukin | #1 |
| allergic conjunctivitis drop | #1 |
| iop akc | #1 |
| allerwatch tests | #1 |
| allergic corneal | #1 |
| atopic keratoconjunctivitis akc | #1 |
| akc patients | #1 |
| binocular conjunctivitis | #1 |
| eyewash solution | #1 |
| patients atopic keratoconjunctivitis | #1 |
| production ketotifen fumarate | #1 |
| signs palpebral | #1 |
| dscg symptoms | #1 |
| compared fluorometholone | #1 |
| severe binocular conjunctivitis | #1 |
| drops elicited | #1 |
| experience 01 | #1 |
| itching levocabastine | #1 |
| akc tear | #1 |
| pge2 human conjunctival | #1 |
| allergic postoperative | #1 |
| eyewash solution bak | #1 |
| sodium ophthalmic solution | #1 |
| severe conjunctivitis eyes | #1 |
| 01 tacrolimus eye | #1 |
| bromfenac sodium | #1 |
| tranilast eotaxin1 | #1 |
| fml dscg | #1 |
| fml administered | #1 |
| improvement combinedtreatment | #1 |
| capilia adeno eye | #1 |
| subjective ocular symptoms | #1 |
| akc compared | #1 |
| talymus | #1 |
| inhibition eotaxin1 | #1 |
| dscg bf | #1 |
| action child conjunctivitis | #1 |
| eyewash solutions | #1 |
| stat6results | #1 |
| fml 002 | #1 |
| accuracy conjunctivitis | #1 |
| radioimmunoassay il4 | #1 |
| atopic keratoconjunctivitis | #1 |
| diseases tear | #1 |
| patients severe conjunctivitis | #1 |
| rapid ophthalmic | #1 |
| rsv conjunctival | #1 |
| exacerbation vkc | #1 |
| eyebon eye | #1 |
| tacrolimus eye drop | #1 |
| akc | #1 |
| instillation symptoms | #1 |
| tears allergic patients | #1 |
| adult cedrus conjunctivitis | #1 |
| instillation bromfenac | #1 |
| allerwatch diagnostic accuracy | #1 |
| tears conjunctival fibroblasts | #1 |
| levocabastine artificial | #1 |
| selected fml | #1 |
| conjunctivitis treated | #1 |
| dscg 005 | #1 |
| conjunctival cedar | #1 |
| cedrus conjunctivitis | #1 |
| commercial eyewash solutions | #1 |
| therapy levocabastine | #1 |
| bf concomitantly | #1 |
| eyewash solutions bak | #1 |
| systemic control pain | #1 |
| bf fml | #1 |
| vkc akc | #1 |
| eye itching | #1 |
| cd3 cd4bearing cells | #1 |
| allergic enzyme | #1 |
| il4 causing | #1 |
| eotaxin1 production | #1 |
| allerwatch positivity rate | #1 |
| prostaglandin tears | #1 |
| allergic conjunctivitis efficacy | #1 |
| hyperemia pain | #1 |
| patients capilia | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| solution allergic | #1 |
| vkc cases | #1 |
| allergenmediated conjunctivitis | #1 |
| commercial washing solution | #1 |
| satisfaction suspensions | #1 |
| eye allerwatch | #1 |
| bromfenac sodium treatment | #1 |
| il4 tear | #1 |
| ketotifen fumarate dexamethasone | #1 |
| scleritis tacrolimus | #1 |
| conjunctival fibroblasts production | #1 |
| bak epithelium disorders | #1 |
| keratoconjunctivitis background | #1 |
| 10 objective signs | #1 |
| antagonists child conjunctivitis | #1 |
| postoperative conjunctivitis | #1 |
| bromfenac sodium bf | #1 |
| epithelial pge2 | #1 |
| tranilast dexamethasone | #1 |
| conjunctival fibroblasts | #1 |
| positivity rate allerwatch | #1 |
| rate allerwatch | #1 |
| production conjunctival fibroblasts | #1 |
| tacrolimus eye drops | #1 |
| primary human conjunctival | #1 |
| 01 ophthalmic solution | #1 |
| tacrolimus ophthalmic | #1 |
| tranilast production | #1 |
| washing allergens | #1 |
| fourgraded severity | #1 |
| adjuvant fluorometholone | #2 |
| selected bf | #2 |
| epinastine superiority | #2 |
| tacrolimus 1 month | #2 |
| recurrence corneal complications | #2 |
| lessen steroid | #2 |
| patients shield ulcers | #2 |
| adjuvant betamethasone | #2 |
| resolution thermography | #2 |
| akc sac patients | #2 |
| largescale study protocol | #2 |
| simple resection regrowth | #2 |
| limbal swelling | #2 |
| reported eotaxin | #2 |
| mmc aided | #2 |
| epitheliopathy corneal | #2 |
| severe allergic conjunctivitis | #2 |
| based papillae | #2 |
| papilla accompanied | #2 |
| tacrolimus detection | #2 |
| allergy accompanied | #2 |
| ulcer complain | #2 |
| folliculosis papillae | #2 |
| tears akc | #2 |
| shield ulcers patients | #2 |
| eyes betamethasone | #2 |
| cutometer sem575 | #2 |
| bromfenac ophthalmic solution | #2 |
| improvement corneal fluorescein | #2 |
| papillae akc | #2 |
| 001 brush | #2 |
| swelling folliculosis | #2 |
| patients shield | #2 |
| drop steroid | #2 |
| patients corneal ulcers | #2 |
| topical antiallergic agents | #2 |
| olopatadine ocular | #2 |
| sodium ophthalmic | #2 |
| brush cytology patients | #2 |
| corneal epithelial signs | #2 |
| eyelid elasticity | #2 |
| conclusions bromfenac | #2 |
| conjunctiva papillary | #2 |
| topical tacrolimus combination | #2 |
| epitheliopathy shield | #2 |
| baseline papillae | #2 |
| epitheliopathy patients | #2 |
| study designopen cohort | #2 |
| diabetic patients ono2235 | #2 |
| vkc japan | #2 |
| japan topical tacrolimus | #2 |
| tacrolimus shield | #2 |
| conjunctiva bulbar | #2 |
| evaluate superiority | #2 |
| effects topical tacrolimus | #2 |
| conjunctivitis retrospective | #2 |
| drops refractory | #2 |
| formation akc | #2 |
| premedication combined | #2 |
| solution epinastine | #2 |
| severity eyelid | #2 |
| ecp severity markers | #2 |
| tacrolimus tonometry | #2 |
| bromfenac effective | #2 |
| cedrus conjunctiva | #2 |
| japan akc | #2 |
| diathesis subjective | #2 |
| benzophenones bromobenzenes | #2 |
| drops conjunctival | #2 |
| bovine entericcoated lactoferrin | #2 |
| 18 akc | #2 |
| corneal epitheliopathy | #2 |
| pollutants prevalence | #2 |
| allergic conjunctivitis levocabastine | #2 |
| normal blinking patients | #2 |
| conjunctivitis adolescent | #2 |
| akc young adult | #2 |
| factor vkc | #2 |
| score adjustments | #2 |
| administered elf bovine | #2 |
| correlation fluorescein | #2 |
| eyelid atopic dermatitis | #2 |
| excision cobblestone | #2 |
| tacrolimus lessen | #2 |
| environmental studies prevalence | #2 |
| month eyewash | #2 |
| giant papillary formation | #2 |
| mmc 7 eyes | #2 |
| proliferative called | #2 |
| atopic diagnostic techniques | #2 |
| 2helper cell | #2 |
| sac healthy | #2 |
| epitheliopathy steroids | #2 |
| extents corneal | #2 |
| aided papillary | #2 |
| elasticity severity | #2 |
| allergic diagnosis | #2 |
| treatment total signs | #2 |
| concomitantly abovementioned | #2 |
| efficacy severe akc | #2 |
| scores tacrolimus | #2 |
| suspension lactoferrin | #2 |
| eyes 824 | #2 |
| csa akc | #2 |
| metaregression analysis glaucoma | #2 |
| eyewash 005 | #2 |
| height papillae | #2 |
| drops hyperemia | #2 |
| papillary excision | #2 |
| epinastine 15 minutes | #2 |
| severity corneal damage | #2 |
| eosinophils corneal damage | #2 |
| ensured proving | #2 |
| dryness scores | #2 |
| period rhodanine | #2 |
| bromfenac sodium bromfenac | #2 |
| simple papillary resection | #2 |
| edema corneal damage | #2 |
| endpoint itching scale | #2 |
| excision cobblestonelike papillae | #2 |
| fluorescein conjunctival injection | #2 |
| corneal lesions | #2 |
| effects tacrolimus | #2 |
| cornea grading | #2 |
| methods thirtysix patients | #2 |
| conjunctivitis representative | #2 |
| akc 10 eyes | #2 |
| complain foreign | #2 |
| sem575 | #2 |
| lid skin | #2 |
| score topical | #2 |
| lactoferrin 01 | #2 |
| vkc 5 | #2 |
| drop concomitantly | #2 |
| unpaired ttest talymus | #2 |
| tears thiazolidines | #2 |
| corneal damage patients | #2 |
| tacrolimus iop | #2 |
| allergic endophthalmitis | #2 |
| including akc | #2 |
| decrease corneal temperature | #2 |
| muc16 immunohistochemistry | #2 |
| akc levels | #2 |
| corneal ulcers patients | #2 |
| diagnosis ensured | #2 |
| akc 1 | #2 |
| 062 tear | #2 |
| conjunctivitis condition | #2 |
| ocular surface mucin | #2 |
| signs decreased | #2 |
| corneal complications height | #2 |
| ceramide gel application | #2 |
| conjunctivitis epitheliopathy | #2 |
| total signs symptoms | #2 |
| papillae mucous discharge | #2 |
| akc adolescent | #2 |
| allergic conjunctivitis ige | #2 |
| neutrophils brush | #2 |
| olopatadine cedar | #2 |
| regrowth papillae | #2 |
| detected akc | #2 |
| inflammatory child child | #2 |
| conjunctivitis 10 | #2 |
| nonpreserved eyewash solution | #2 |
| corneal damage height | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| conjunctival injection edema | #2 |
| patients tacrolimus eye | #2 |
| steroids epitheliopathy | #2 |
| keratoconjunctivitis age | #2 |
| cytodiagnosis dermatitis | #2 |
| ecp levels akc | #2 |
| correlation eosinophils | #2 |
| akc adult | #2 |
| papillae preventing | #2 |
| akc 6 | #2 |
| severity corneal complications | #2 |
| plaques 791 | #2 |
| 1 month tacrolimus | #2 |
| severity corneal lesions | #2 |
| epinastine ophthalmic solution | #2 |
| post cataract surgery | #2 |
| corneal lesions regrowth | #2 |
| mucin analyzed | #2 |
| keratoconjunctivitis corneal | #2 |
| female humans akc | #2 |
| tarsal brush | #2 |
| formation palpebral | #2 |
| dermatitis remission | #2 |
| sodium bromfenac | #2 |
| mucous discharge severity | #2 |
| iop topical steroids | #2 |
| hyperemia lacrimation | #2 |
| control subjects eyes | #2 |
| akc patients correlation | #2 |
| steroid metaregression | #2 |
| papillary formation | #2 |
| asthma heart diseases | #2 |
| signs blood concentration | #2 |
| betamethasone glaucoma | #2 |
| pge2 tears | #2 |
| sem575 clinical | #2 |
| treated bromfenac | #2 |
| correlation neutrophils | #2 |
| tacrolimus topical | #2 |
| corneal epitheliopathy score | #2 |
| treatment shield ulcer | #2 |
| tacrolimus 12 weeks | #2 |
| akc treated | #2 |
| adjustments epitheliopathy | #2 |
| ari ocular | #2 |
| oral ari ono2235 | #2 |
| administered elf | #2 |
| scores papillary | #2 |
| tear film layer | #2 |
| noninferiority olopatadine | #2 |
| adjuvant fluorometholone 95 | #2 |
| giant papillae formation | #2 |
| oral ari administration | #2 |
| recurrence corneal lesions | #2 |
| prevalence akc | #2 |
| treatment atopic blepharitis | #2 |
| conventional antiallergic drugs | #2 |
| akc 10 | #2 |
| cobblestonelike papillae | #2 |
| papillae severe | #2 |
| ketotifen dexamethasone | #2 |
| epitheliopathy score | #2 |
| olopatadine visit | #2 |
| serum allergic parameters | #2 |
| treatment tear | #2 |
| akc aureus | #2 |
| patients severe akc | #2 |
| japan topical | #2 |
| accompanied subjective | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| tacrolimus published data | #2 |
| elasticity eyelid | #2 |
| atopic blepharitis | #2 |
| objective signs baseline | #2 |
| placebo noninferiority | #2 |
| total clinical signs | #2 |
| corneal recurrences | #2 |
| test papillae | #2 |
| oral ari | #2 |
| conjunctivitis proliferative | #2 |
| adjustments epitheliopathy score | #2 |
| skin elasticity patients | #2 |
| regrowth 7 eyes | #2 |
| allergic conjunctivitis akc | #2 |
| suspension talymus | #2 |
| sem575 quantitatively | #2 |
| lesions allergic | #2 |
| blepharitis ceramides | #2 |
| tear ige correlation | #2 |
| conjunctiva atopic | #2 |
| superiority epinastine | #2 |
| talymus akc | #2 |
| production specular | #2 |
| ophthalmic nsaid | #2 |
| rhodanine rose | #2 |
| conjunctival injection reduction | #2 |
| akc allergic diagnosis | #2 |
| air pollutants prevalence | #2 |
| eyelid atopic | #2 |
| deqs tear | #2 |
| edema height | #2 |
| seasonal allergic conjunctivitis | #2 |
| papillae limbus | #2 |
| disease antiallergic | #2 |
| eyelid skin elasticity | #2 |
| defined conjunctival | #2 |
| immunoregulatory effects study | #2 |
| administration specular | #2 |
| lacrimation objective | #2 |
| corneal temperature patients | #2 |
| bovine placebo | #2 |
| treatment ecp concentrations | #2 |
| epitheliopathy refractory | #2 |
| nonwash | #2 |
| brush cytology samples | #2 |
| cac test | #2 |
| corneal findings | #2 |
| oral aldose | #2 |
| neutrophils corneal damage | #2 |
| refractory allergic | #2 |
| lower conjunctival sacs | #2 |
| aureussecreted enterotoxins | #2 |
| conjunctivitis purpose | #2 |
| improvement vital staining | #2 |
| solutions japan | #2 |
| tacrolimus detection limit | #2 |
| conjunctival findings severity | #2 |
| conjunctival corneal cells | #2 |
| 95 adjuvant betamethasone | #2 |
| representative subjective | #2 |
| elevation tacrolimus | #2 |
| vkc papillae | #3 |
| insufficient tear supply | #3 |
| vkc exacerbation | #3 |
| treatment skin elasticity | #3 |
| diclofenac epithelium | #3 |
| severe allergic patients | #3 |
| drop selected | #3 |
| dramatic healing | #3 |
| signs remission | #3 |
| 5 eyes akc | #3 |
| adedry eye | #3 |
| 21 akc | #3 |
| tissue remodeling exacerbation | #3 |
| titers ade | #3 |
| conjunctiva allergic | #3 |
| underwent staining | #3 |
| il1beta th2 | #3 |
| 5ac mrna | #3 |
| pm25 outpatient attendance | #3 |
| akc dyes humans | #3 |
| metry dfna | #3 |
| vkc sac | #3 |
| oct graticule | #3 |
| eyes control subjects | #3 |
| autumnal pollen | #3 |
| hydrochloride 01 | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| cornea atopic | #3 |
| ocular surface diabetes | #3 |
| cholinergic treatment response | #3 |
| eyes allergic | #3 |
| vkc differences | #3 |
| ssdry | #3 |
| 5ac brush | #3 |
| dfna diclofenac epithelium | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| postsurgical conjunctivitis | #3 |
| vivo corneal akc | #3 |
| eyes akc | #3 |
| existence par2 mrna | #3 |
| oct tmh | #3 |
| erosions refractory | #3 |
| akc eyes | #3 |
| nuclei vkc | #3 |
| akc serum periostin | #3 |
| outpatient attendance july | #3 |
| keratoconjunctivitis leupeptins | #3 |
| akc comorbidities | #3 |
| conjunctiva conjunctivitis | #3 |
| 005 mmc | #3 |
| epinastine placebo | #3 |
| antieaigg | #3 |
| nbs subbasal | #3 |
| allergic patients conjunctivitis | #3 |
| cooling cataract | #3 |
| tmh measurement | #3 |
| vkc 5 eyes | #3 |
| formation vkc | #3 |
| histamine conjunctival cells | #3 |
| tear periostin patients | #3 |
| patching patient | #3 |
| laser cellflaremetry | #3 |
| conjunctival disease | #3 |
| papillae morphometric | #3 |
| superficial cells conjunctiva | #3 |
| increased comfort | #3 |
| akc atopic dermatitis | #3 |
| periostin comorbidities | #3 |
| rose bengal akc | #3 |
| 22 eyes 100 | #3 |
| prophylaxis conjunctival | #3 |
| akc periostin | #3 |
| laser flarecellmetry | #3 |
| periostin topical | #3 |
| akc higher | #3 |
| tryptase increases | #3 |
| topical cyclosporine 01 | #3 |
| measurements schirmer | #3 |
| 12 akc patients | #3 |
| insensible administration insensible | #3 |
| allergic conjunctivitis aged | #3 |
| aureus akc patients | #3 |
| ophthalmic solution nsaid | #3 |
| allergic corneal diseases | #3 |
| outpatient visits july | #3 |
| aged biological dressings | #3 |
| association outpatient attendance | #3 |
| vkc long | #3 |
| papillary regrowth | #3 |
| evaluate tear | #3 |
| temperature evaluate | #3 |
| conjunctival corneal | #3 |
| corneal epithelial structure | #3 |
| lower muc5ac | #3 |
| vkc fibronectin | #3 |
| conjunctivitis benzamidines | #3 |
| scale tmh | #3 |
| inflammation mmc | #3 |
| akc confocal microscopy | #3 |
| benzamidine par2 | #3 |
| il1beta th2 cytokines | #3 |
| tear periostin comorbidities | #3 |
| phenomena tacrolimus | #3 |
| par2 benzamidines blotting | #3 |
| infrared radiation thermography | #3 |
| central corneal temperature | #3 |
| par2 cultured | #3 |
| healing dramatic healing | #3 |
| mmc authors | #3 |
| ari corneal | #3 |
| normal controls collagens | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| 12 akc | #3 |
| ulcers plaques | #3 |
| sensitivity tear | #3 |
| protein conjunctival fibroblasts | #3 |
| fluorescein scale | #3 |
| techniques tears | #3 |
| papillary resection | #3 |
| efficacy bromfenac | #3 |
| patients tmh measurements | #3 |
| study cutometer | #3 |
| lacrimal punctal occlusion | #3 |
| insufficient tear | #3 |
| cases vernal | #3 |
| eye washing | #3 |
| periostin akc | #3 |
| conjunctivitis allergic | #3 |
| allerwatch | #3 |
| thermography evaluate | #3 |
| fibronectin vkc | #3 |
| solutions prospective | #3 |
| tryptase conjunctiva | #3 |
| histamine cedar pollen | #3 |
| pretreatment docosahexaenoic acid | #3 |
| drops treat | #3 |
| mmc excision | #3 |
| cells brush cytology | #3 |
| antiallergic eye drop | #3 |
| prospectively diclofenac | #3 |
| dfna eye | #3 |
| akc confocal | #3 |
| outpatient visits august | #3 |
| treatment strip meniscometry | #3 |
| pm25 allergic | #3 |
| vkc levels | #3 |
| 005 collagens | #3 |
| immunosuppressive eye | #3 |
| 13 eyes 69 | #3 |
| diclofenac eye drops | #3 |
| superior limbic portion | #3 |
| 1 month initiation | #3 |
| fibers lnfs | #3 |
| strip meniscometry testing | #3 |
| mmcaided papillary resection | #3 |
| allergic corneal ulcer | #3 |
| 3 sjögrens syndrome | #3 |
| akc higher muc1 | #3 |
| samples correlate | #3 |
| severe allergy patients | #3 |
| papillae upper | #3 |
| superior keratoconjunctiva | #3 |
| pollen august | #3 |
| diseases acds | #3 |
| akc persistent | #3 |
| technique 2 eyes | #3 |
| histamine cedar | #3 |
| commercial washing | #3 |
| giant papilla | #3 |
| cultured tryptase | #3 |
| eosinophils corneal | #3 |
| glaucoma amniotic | #3 |
| cell metry | #3 |
| tears adolescent | #3 |
| ophthalmic solution placebo | #3 |
| sde controls | #3 |
| operation eye | #3 |
| elisa histamine | #3 |
| patching case | #3 |
| 21 akc patients | #3 |
| ulcers eyes | #3 |
| 111 177 | #3 |
| tears treatment | #3 |
| lnfs nbs | #3 |
| surgery dfna | #3 |
| interleukin4 histamine | #3 |
| conjunctivitis pm25 | #3 |
| sligkv examined | #3 |
| dscg administration | #3 |
| 01 ophthalmic | #3 |
| portable recordable | #3 |
| tear il13 | #3 |
| 01 bromfenac | #3 |
| muc1 brush cytology | #3 |
| patients pilocarpine tablets | #3 |
| akc tear periostin | #3 |
| injections keratoconjunctivitis | #3 |
| akc alterations | #3 |
| aged elisa | #3 |
| nonpreserved artificial tears | #3 |
| ulcer akc | #3 |
| proving type | #3 |
| ebv ade | #3 |
| keratoconjunctivitis vkc | #3 |
| corneal ulceration role | #3 |
| local tear deficiency | #3 |
| icecold eye mask | #3 |
| improvement squamous metaplasia | #3 |
| tear periostin | #3 |
| higher muc1 eyes | #3 |
| flare metry | #3 |
| corneal complications1 | #3 |
| technique uncontrollable | #3 |
| allergic cornea | #3 |
| corneal akc | #3 |
| pollen postoperative | #3 |
| hyperemia allergic | #3 |
| relevant factor exacerbation | #3 |
| formation vernal | #3 |
| production conjunctival | #3 |
| diabetic corneal disease | #3 |
| pilocarpine visante | #3 |
| vkc eyes | #3 |
| decline corneal | #3 |
| induced inflammation lenses | #3 |
| dfna eye dfna | #3 |
| dibenzoxepins female | #3 |
| vkc cell | #3 |
| underwent periodic | #3 |
| healing allergic | #3 |
| existence par2 | #3 |
| antibody titers ade | #3 |
| cases vkc | #3 |
| permeability postoperatively | #3 |
| histamine superficial cells | #3 |
| rtpcr par2 | #3 |
| fluorescein glycyrrhizic | #3 |
| interleukin4 tacrolimus | #3 |
| uncontrollable glaucoma | #3 |
| july pm25 | #3 |
| akc rose bengal | #3 |
| tear periostin biomarker | #3 |
| sdedry eye | #3 |
| macroerosions | #3 |
| nbs normal eyes | #3 |
| membrane uncontrollable | #3 |
| dfna control | #3 |
| conjunctivitis negative | #3 |
| healed amniotic | #3 |
| histamine specimens | #3 |
| eyes vkc | #3 |
| 005 ophthalmic solution | #3 |
| dry eye eye | #3 |
| ecp severity | #3 |
| treatment vernal | #3 |
| fibronectin normal controls | #3 |
| child conjunctiva | #3 |
| differences dfna | #3 |
| allergic postsurgical | #3 |
| weekly average values | #3 |
| eye cooling | #3 |
| traumatic swelling | #3 |
| reaction conjunctiva | #3 |
| cytology impression | #3 |
| techniques conjunctivitis | #3 |
| akc biomarkers | #3 |
| vkc relevant factor | #3 |
| ulcer persistent | #3 |
| cell flare count | #3 |
| alterations tear | #3 |
| lamp device | #3 |
| scored global | #3 |
| conjunctivitis lymphocytes | #3 |
| epithelium adverse | #3 |
| conjunctival fibroblasts tryptase | #3 |
| treatment oral pilocarpine | #3 |
| ded 1 | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| akc crth2 | #4 |
| allergic conjunctival diseases | #4 |
| performed tears | #4 |
| atopic ocular | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| giemsas staining | #4 |
| individuals pgd2 | #4 |
| disease akc | #4 |
| patients topical cyclosporine | #4 |
| topical 01 tacrolimus | #4 |
| temperature corneal | #4 |
| eyes sac | #4 |
| compared vkc | #4 |
| defensins conjunctivitis | #4 |
| vkc 4 | #4 |
| portable slit | #4 |
| solutions piperidines | #4 |
| cytometry mild cases | #4 |
| thinoptx intraocular | #4 |
| atopic dermatitis remission | #4 |
| rsv allergic reaction | #4 |
| cytology goblet | #4 |
| goblet cell muc5ac | #4 |
| muc5ac alterations | #4 |
| metaregression analysis effects | #4 |
| healthy individuals rtpcr | #4 |
| controls interferometry | #4 |
| acds ophthalmologists | #4 |
| 0001 brush | #4 |
| muc5ac brush cytology | #4 |
| corneal temperature blink | #4 |
| allergic cytological | #4 |
| patient atopic keratoconjunctivitis | #4 |
| diameter allergen | #4 |
| histamine h1 antagonist | #4 |
| bromfenac eye drops | #4 |
| mucins 1 | #4 |
| akc crth2 expression | #4 |
| mucin mucins tears | #4 |
| dust wheal | #4 |
| simple resection | #4 |
| corneal ulcers eyes | #4 |
| diseases portable | #4 |
| 020 013 | #4 |
| muc16 muc5ac alterations | #4 |
| eosinophil toxic activity | #4 |
| conjunctivitis ige | #4 |
| akc immunologic receptors | #4 |
| vmr 3 months | #4 |
| stimulation chemokine expression | #4 |
| allergic conjunctivitis rsv | #4 |
| ophthalmologists evaluated | #4 |
| steroids fluorometholone | #4 |
| patient eyes fluorescein | #4 |
| clinical conjunctival | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| acuity akc | #4 |
| ige conjunctival | #4 |
| cells lnfs | #4 |
| eosinophils receptor crth2 | #4 |
| conjunctival proliferative | #4 |
| specimens underwent | #4 |
| membrane patching | #4 |
| cytometry mild | #4 |
| 18 akc patients | #4 |
| implantation rollable | #4 |
| studied corneal | #4 |
| epithelial disease patients | #4 |
| corneal temperature eye | #4 |
| fva treatment | #4 |
| 10 seconds temperature | #4 |
| grade dry eye | #4 |
| weeks vital | #4 |
| conjunctiva density | #4 |
| thinoptx lens | #4 |
| rsv conjunctival epithelium | #4 |
| interferometry lipids | #4 |
| tear function test | #4 |
| lesions regrowth | #4 |
| crth2 peripheral | #4 |
| infected conjunctival | #4 |
| rsv conjunctiva | #4 |
| tear function patients | #4 |
| hydrochloride ophthalmic | #4 |
| pgd2dependent migration | #4 |
| severe vkc patients | #4 |
| dscg day | #4 |
| oedema papillary | #4 |
| interferometry controls | #4 |
| greater 3 grade | #4 |
| greater concentrations tears | #4 |
| thermometer 20 | #4 |
| 34 15 seconds | #4 |
| conjunctiva differences | #4 |
| cornea grading scale | #4 |
| proteinchip array elisa | #4 |
| surface muc5ac | #4 |
| sio2 20 | #4 |
| treatment vmr | #4 |
| akc sac | #4 |
| akc chemotaxis | #4 |
| july pollen | #4 |
| cell muc5ac | #4 |
| tomography tear | #4 |
| patients epithelial disease | #4 |
| metaplasia reduction | #4 |
| sensitization asian dust | #4 |
| muc16 goblet | #4 |
| 33 chemokines | #4 |
| surface conjunctival | #4 |
| sterilized asian dust | #4 |
| 3004 respondents | #4 |
| lower tear clearance | #4 |
| interleukin2 tears | #4 |
| conjunctivitis vkc | #4 |
| levocabastine h1 | #4 |
| underwent corneal | #4 |
| pgd2 normal volunteers | #4 |
| allergies blinding | #4 |
| blinding purpose | #4 |
| adolescent betamethasone | #4 |
| akc healthy | #4 |
| eyes epithelial disease | #4 |
| pcr epithelial | #4 |
| pathogenesis noninfectious | #4 |
| allergic conjunctival | #4 |
| sterilized asian | #4 |
| highrisk glaucoma patients | #4 |
| assay pgd2 | #4 |
| ulcers mucin | #4 |
| recordable slit | #4 |
| ulcers atopic | #4 |
| interferometry grade | #4 |
| papillae normal | #4 |
| epithelial disease eyes | #4 |
| implantation thinoptx | #4 |
| muc1 2 | #4 |
| crth2 akc | #4 |
| par2 mrna protein | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| allergic fibroblasts | #4 |
| conventional portable | #4 |
| ulcers control subjects | #4 |
| p0001 impression | #4 |
| erosion shield | #4 |
| vkc normal controls | #4 |
| eyes ulcers | #4 |
| mucins tears mucin | #4 |
| 2 4 alterations | #4 |
| eye sjögrens syndrome | #4 |
| thinoptx acrysof | #4 |
| level conjunctiva | #4 |
| immunologic receptors akc | #4 |
| cases sufficient examination | #4 |
| photophobia diagnosis | #4 |
| sensation tears | #4 |
| eye wash solution | #4 |
| untreated asian dust | #4 |
| persistent 6 | #4 |
| 4 chemokines stimulation | #4 |
| conjunctivitis methods | #4 |
| conjunctival papillary | #4 |
| fibroblasts primary sources | #4 |
| wilcoxon signed test | #4 |
| bromfenac ophthalmic | #4 |
| patients severe vkc | #4 |
| allergic patients elisa | #4 |
| tablets tears | #4 |
| asian dust extract | #4 |
| vkc male receptors | #4 |
| ari ono2235 | #4 |
| genes conjunctival | #4 |
| inflammation akc | #4 |
| bengal sensation | #4 |
| rejection limbal | #4 |
| corneal safety | #4 |
| eotaxin1 rantes | #4 |
| epithelial cells rsv | #4 |
| eye operation | #4 |
| thermography anterior | #4 |
| treatment vmr values | #4 |
| insignificant epithelial | #4 |
| steroids iop | #4 |
| special brush | #4 |
| levocabastine ophthalmic | #4 |
| allergic conjunctival disease | #4 |
| alterations atopic | #4 |
| akc rtpcr | #4 |
| male ophthalmic | #4 |
| corneal sensitivity measurement | #4 |
| folliculosis | #4 |
| cultured conjunctival | #4 |
| excision papillary | #4 |
| akcaffected patients | #4 |
| corneal sensitivity measurements | #4 |
| ophthalmologists eye drops | #4 |
| eyes akc patients | #4 |
| moisture checker | #4 |
| rose bengal scores | #4 |
| muc5ac mrna expression | #4 |
| pgd2dependent migration eosinophils | #4 |
| completely severe | #4 |
| fungi epidemiologic studies | #4 |
| allergic epidemiologic studies | #4 |
| scores conjunctival | #4 |
| atopic ocular allergies | #4 |
| hypersensitivity mucin | #4 |
| staining muc | #4 |
| 2010 allergic | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| staining muc16 | #4 |
| deqs scores | #4 |
| chemokine genes fibroblasts | #4 |
| p0001 brush | #4 |
| epithelial pge2 production | #4 |
| tear temperature | #4 |
| insignificant epithelial disease | #4 |
| eyes corneal ulcers | #4 |
| trantas | #4 |
| ocular allergic disease | #4 |
| vkc messenger reverse | #4 |
| months papillary | #4 |
| topical oral steroids | #4 |
| noninfectious necrotizing | #4 |
| exponential equation inclination | #4 |
| akc pgd2dependent migration | #4 |
| sac control eyes | #4 |
| thinoptx | #4 |
| drop artificial tears | #4 |
| keratoconjunctivitis purpose | #4 |
| severe ocular allergies | #4 |
| ocular surface epithelial | #4 |
| 061 028 degree | #4 |
| epinastine hydrochloride | #4 |
| tnfalpha30ng | #4 |
| tryptase dose | #4 |
| samples histocytological | #4 |
| chemotaxis conjunctiva | #4 |
| controls interferometry grade | #4 |
| samples immunocytochemical | #4 |
| limbal grafts | #4 |
| keratoconjunctivitis lacrimal | #4 |
| acds conventional | #4 |
| akc healthy individuals | #4 |
| tacrolimus conclusions | #4 |
| sac grade | #4 |
| interferometry 2 | #4 |
| papillae giant | #4 |
| epithelial muc16 | #4 |
| muc5ac brush | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| eyes video | #4 |
| epithelial muc | #4 |
| eyes insignificant | #4 |
| conjunctivitis levels | #4 |
| controls brush cytology | #4 |
| corneal ulcers muc5ac | #4 |
| tears pathogenesis | #4 |
| formation conjunctivitis | #4 |
| eyes thinoptx | #4 |
| correlation outpatient | #4 |
| il4 tears | #4 |
| tears 10 patients | #4 |
| subjects muc5ac | #4 |
| primary sources chemokines | #4 |
| include ocular | #4 |
| defensins greater | #4 |
| microscope evaluating | #4 |
| tears patients | #4 |
| staining ocular | #4 |
| placebo ophthalmic | #4 |
| atopic vernal | #4 |
| aged rose | #4 |
| lower tear function | #4 |
| samples allergic | #4 |
| impression cytology samples | #5 |
| akc patients study | #5 |
| alterations ocular | #5 |
| fibroblasts fibroblast damage | #5 |
| dryeye symptoms treatment | #5 |
| treatment tacrolimus ointment | #5 |
| age 9 ± | #5 |
| ocular surface disorder | #5 |
| topical cyclosporine therapy | #5 |
| eosinophil adherence fibroblasts | #5 |
| postsurgical inflammation | #5 |
| conjunctivitis pollen | #5 |
| conjunctiva mmc | #5 |
| cases tests | #5 |
| disposable eyelidwarming device | #5 |
| treatment dryeye symptoms | #5 |
| adhered corneal | #5 |
| bengal suture | #5 |
| disease conjunctivitis | #5 |
| hel akc | #5 |
| tnfα costimulation | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| solutions pollen | #5 |
| vkc iop | #5 |
| prostaglandin chemotaxis | #5 |
| anterior fluorometry | #5 |
| scans akc | #5 |
| vkc atopic | #5 |
| keratoconjunctivitis objective | #5 |
| ocular allergic | #5 |
| inflammatory cells hel | #5 |
| conjunctival confocal microscopy | #5 |
| lipid oxidation hel | #5 |
| disposable eyelid | #5 |
| thinoptx iol | #5 |
| hel ihc | #5 |
| eosinophils activated fibroblasts | #5 |
| ihc conjunctival inflammation | #5 |
| corneal fibroblasts icam1 | #5 |
| upper palpebral | #5 |
| severe stevensjohnson syndrome | #5 |
| cells vkc | #5 |
| 7 conjunctival | #5 |
| cornea explain | #5 |
| crth2 prostaglandin receptors | #5 |
| 005 schirmer1 | #5 |
| solution olopatadine | #5 |
| meniscus punctal | #5 |
| staining administration | #5 |
| diclofenac eye | #5 |
| ophthalmic test | #5 |
| cornea cytodiagnosis | #5 |
| conjunctiva dermatitis | #5 |
| warmer applied | #5 |
| oct lower | #5 |
| vcam1 fibroblasts | #5 |
| allergic drug therapy | #5 |
| accompanying allergic | #5 |
| stained conjunctival | #5 |
| pgd2 normal | #5 |
| akc acinar | #5 |
| stainings tear | #5 |
| lesion corneal | #5 |
| il4 histamine | #5 |
| simple papillary | #5 |
| impression brush | #5 |
| damaged eosinophil | #5 |
| conventional steroid treatment | #5 |
| 15 minutes dose | #5 |
| controls ebv | #5 |
| adolescent conjunctivitis | #5 |
| warmer improved | #5 |
| conjunctivitis prostaglandin | #5 |
| trantas dots | #5 |
| asthenopia dry | #5 |
| months amniotic | #5 |
| allergic conjunctivitis patients | #5 |
| pm25 outpatient | #5 |
| case corneal ulcer | #5 |
| scores expressibility | #5 |
| antifungal mcfg | #5 |
| accompanied varying | #5 |
| tears received | #5 |
| conjunctival lipid | #5 |
| inflammation mitomycin | #5 |
| younger age effects | #5 |
| hne ihc | #5 |
| akc hel | #5 |
| keratoconjunctivitis giant | #5 |
| schirmer1 test groups | #5 |
| endophthalmitis eosinophils | #5 |
| controls inflammatory cells | #5 |
| equipment dry | #5 |
| damage impression | #5 |
| schiff immunohistochemical | #5 |
| temperature blink | #5 |
| 329±57 years | #5 |
| 20 akc patients | #5 |
| array chemotaxis | #5 |
| staining muc5ac | #5 |
| bromobenzenes cornea | #5 |
| 3 cases followup | #5 |
| treatment shield | #5 |
| wilcoxonmatched pair test | #5 |
| visits july | #5 |
| conjunctival allergen | #5 |
| treatment epinastine | #5 |
| eosinophil adhesion fibroblasts | #5 |
| human conjunctival fibroblasts | #5 |
| regulation allergic cornea | #5 |
| 17 mgd patients | #5 |
| measurements strip | #5 |
| labeling surface akc | #5 |
| histamine superficial | #5 |
| cytokinestimulation | #5 |
| eye warmer | #5 |
| injection conjunctival | #5 |
| local tear | #5 |
| akc normal subjects | #5 |
| fibroblasts eosinophil adherence | #5 |
| 01 mcfg | #5 |
| pretreatment dha | #5 |
| month tear | #5 |
| situ nickend regulation | #5 |
| ulcers controls | #5 |
| signs akc | #5 |
| eye warmer treatment | #5 |
| eosinophils immunologic receptors | #5 |
| lower atopic | #5 |
| intraoperative mitomycin excision | #5 |
| mcfg eye | #5 |
| supernatants conjunctival | #5 |
| severity akc | #5 |
| ophthalmic suspension | #5 |
| akc laser | #5 |
| eye circulating | #5 |
| 376±56 years | #5 |
| allergic female | #5 |
| diseases required | #5 |
| alpha allergic | #5 |
| allergic cyclosporine | #5 |
| crth2 eosinophils | #5 |
| conjunctival inflammatory status | #5 |
| females akc | #5 |
| thiazolidines administration | #5 |
| 0001 strip | #5 |
| ocular anesthesia | #5 |
| punctal occlusion oct | #5 |
| 310±165 years | #5 |
| allergic keratopathy | #5 |
| stimulated conjunctival | #5 |
| akc ecp | #5 |
| samples akc | #5 |
| status confocal | #5 |
| akc disease | #5 |
| worse akc | #5 |
| corneal involvement | #5 |
| 20 sio2 | #5 |
| visits august | #5 |
| mitomycin excision | #5 |
| layer mgd | #5 |
| severe conjunctivitis | #5 |
| dryeye symptoms | #5 |
| ulcer dermatitis | #5 |
| hel cytokines | #5 |
| anterior scleritis patients | #5 |
| study epinastine | #5 |
| 5 females akc | #5 |
| conjunctival brush cytology | #6 |
| dfna | #6 |
| grading tear | #6 |
| strip meniscometry scores | #6 |
| fluorometholone follow | #6 |
| elasticity cutometer | #6 |
| patients seldi | #6 |
| treatment tacrolimus | #6 |
| density conjunctival | #6 |
| il4 il2r | #6 |
| twicedaily instillation | #6 |
| cgvhd improvements | #6 |
| 20 pbs | #6 |
| july correlation | #6 |
| obstructive mgd patients | #6 |
| conjunctivitis sac | #6 |
| severe vkc | #6 |
| sde ade | #6 |
| elevation refractory | #6 |
| noninvasive suction device | #6 |
| allergens cedrus | #6 |
| scores goblet | #6 |
| agents interferometry | #6 |
| differences tear | #6 |
| controlling eyelid | #6 |
| hyperemia imidazoles | #6 |
| pcr muc5ac | #6 |
| coated elf | #6 |
| functions topical | #6 |
| extract sterilized | #6 |
| tryptase proliferation | #6 |
| treatment postoperative inflammation | #6 |
| corneal temperature | #6 |
| pathogenesis ocular | #6 |
| solution commercial | #6 |
| fva landolt | #6 |
| levocabastine effective | #6 |
| tear stability values | #6 |
| dermatitis scored | #6 |
| corneal damage | #6 |
| atopic eyelids | #6 |
| specimens akc | #6 |
| diseases periostin | #6 |
| antiallergic eye | #6 |
| rate tbut | #6 |
| remodeling vkc | #6 |
| eosinophils crth2 | #6 |
| patients visante | #6 |
| corneal fibroblasts pathogenesis | #6 |
| itching conjunctival | #6 |
| conjunctival diseases | #6 |
| topical cys treatment | #6 |
| severe ocular inflammation | #6 |
| ocular surface findings | #6 |
| severe stevens | #6 |
| challenge cac | #6 |
| inflammatory cell densities | #6 |
| hyperemia swelling | #6 |
| tear meniscus patients | #6 |
| eye evaluated | #6 |
| defect penetrating | #6 |
| signs scored | #6 |
| tear eosinophil | #6 |
| tears acinar | #6 |
| dressings female | #6 |
| chloride eye | #6 |
| fibroblasts conjunctival | #6 |
| intolerable irritation | #6 |
| akc refractory | #6 |
| levels air pollutants | #6 |
| 4 muc | #6 |
| cys ocular | #6 |
| ade sde | #6 |
| tbut vital | #6 |
| samples underwent | #6 |
| ecp markers | #6 |
| tear ecp | #6 |
| symptoms vkc | #6 |
| female fluorometholone | #6 |
| findings dry eye | #6 |
| ointment blood | #6 |
| conjunctival confocal | #6 |
| akc vernal keratoconjunctivitis | #6 |
| tacrolimus chronic | #6 |
| betamethasone oral | #6 |
| papillae mucous | #6 |
| oxidation hel | #6 |
| concomitant eye | #6 |
| evaporation vital | #6 |
| schirmer1 test values | #6 |
| cyclosporine 01 | #6 |
| induced tear | #6 |
| edema severity | #6 |
| regulation benzamidines | #6 |
| topical cys | #6 |
| allergic diathesis | #6 |
| topical levocabastine | #6 |
| eosinophil recruiting chemokines | #6 |
| sac vkc | #6 |
| upper tarsal conjunctiva | #6 |
| instability conjunctival | #6 |
| defect ped | #6 |
| ocular fatigue | #6 |
| rtpcr epithelial cells | #6 |
| rose bengal dyes | #6 |
| testing tear | #6 |
| syndrome tablets | #6 |
| 4 9 genes | #6 |
| severe vernal | #6 |
| tranilast inhibition | #6 |
| examinations tear | #6 |
| tears xerophthalmia | #6 |
| bengal vital stainings | #6 |
| eyes atopic | #6 |
| dust asian | #6 |
| allergic conjunctivitis cac | #6 |
| pgd2 dependent | #7 |
| accommodating intraocular lens | #7 |
| eczema frequently | #7 |
| conjunctival brush | #7 |
| rose bengal fluorescein | #7 |
| sources chemokines | #7 |
| ulcers revealed | #7 |
| nerves tear | #7 |
| adult blepharitis | #7 |
| cytology differ | #7 |
| examination tear | #7 |
| steroidal benzophenones | #7 |
| 10 clinical signs | #7 |
| attendance allergic | #7 |
| inhibitor ono2235 | #7 |
| injection oedema | #7 |
| gpc vkc | #7 |
| concentrations conjunctival | #7 |
| eyelid surface | #7 |
| alpha tears | #7 |
| improvements symptom scores | #7 |
| crth2 normal | #7 |
| tears alpha | #7 |
| sensation symptom | #7 |
| revealed eosinophils | #7 |
| nonparametric tears | #7 |
| pathogenesis subsequent | #7 |
| allergic eyelid | #7 |
| severe persistent cases | #7 |
| thought pathogenesis | #7 |
| conjunctiva brush | #7 |
| chemotaxis eosinophils | #7 |
| prostaglandin atopic | #7 |
| solution bf | #7 |
| 0001 impression | #7 |
| procedures radioimmunoassay | #7 |
| mmc observed | #7 |
| papillae formation | #7 |
| corneal lesion | #7 |
| conjunctivitis risk | #7 |
| 4 tear | #7 |
| necrotizing anterior | #7 |
| normal blinking | #7 |
| cases preventing | #7 |
| mmc 005 | #7 |
| tacrolimus topical steroids | #7 |
| tacrolimustreated eyes | #7 |
| ocular inflammatory disorder | #7 |
| status atopic | #7 |
| tears th2 | #7 |
| increases proliferative | #7 |
| patients comfort level | #7 |
| eyes ophthalmologists | #7 |
| incidence meibomian | #7 |
| conjunctival inflammatory | #7 |
| administration fluorescein | #7 |
| mucins tears | #7 |
| allergic dna | #7 |
| hyperemia adverse | #7 |
| silicone plugs | #7 |
| ulceration healthy | #7 |
| vkc gpc | #7 |
| collected brush | #7 |
| mucins periodic | #7 |
| tmh measurements | #7 |
| development allergic conjunctivitis | #7 |
| hrtii rcm | #7 |
| neutrophils corneal | #7 |
| meniscometry testing | #7 |
| pge2 cox2 levels | #7 |
| evaluation eyelid | #7 |
| suspension 01 | #7 |
| key prostaglandin | #7 |
| age 325 years | #7 |
| sensitization asian | #7 |
| tear supply | #7 |
| surgery cooling | #7 |
| western blotting nfκb | #7 |
| conjunctival complications | #7 |
| conjunctivitis dry | #7 |
| superiority placebo | #7 |
| ulcer corneal | #7 |
| amniotic membrane patching | #7 |
| conclusion mmc | #7 |
| flare counts | #8 |
| betamethasone calcineurin | #8 |
| ihc hel | #8 |
| conjunctivitis eyes | #8 |
| patients corneal | #8 |
| pathogenesis test | #8 |
| stainings schirmer | #8 |
| age 170 ± | #8 |
| fva measurements | #8 |
| classified allergic | #8 |
| correlation vital | #8 |
| values slit | #8 |
| radiation thermography | #8 |
| allergic dibenzazepines | #8 |
| corneal ulcer | #8 |
| blinking desiccation | #8 |
| diameter acinar | #8 |
| graticule scale | #8 |
| patients vkc | #8 |
| occlusion lacrimal | #8 |
| staining hel | #8 |
| stained hel | #8 |
| il4 enzyme | #8 |
| meniscometry tear | #8 |
| ccl5 conjunctiva | #8 |
| infrared radiation thermometry | #8 |
| sac akc | #8 |
| rollable intraocular | #8 |
| par2 mast cells | #8 |
| teros | #8 |
| conjunctival sensation | #8 |
| microscopy conjunctival | #8 |
| transient burning sensation | #8 |
| meniscometry scores | #8 |
| scores teros | #8 |
| conjunctival findings | #8 |
| 006 degree | #8 |
| akc subjects | #8 |
| corneal fibroblasts tnfalpha | #8 |
| akc patients controls | #8 |
| keratocytes cytokines | #8 |
| induced intraocular | #8 |
| chemotaxis pgd2 | #8 |
| definite dry eye | #8 |
| underwent tear | #8 |
| hoc analysis study | #8 |
| techniques keratoconjunctivitis | #8 |
| fluorescein rose bengal | #8 |
| pollen odds | #8 |
| superficial cells groups | #8 |
| palpebral bulbar | #8 |
| controls seldi | #8 |
| teros values | #8 |
| itching hyperemia | #8 |
| 4 chemokines | #8 |
| blink patients | #8 |
| alterations cornea | #8 |
| mitomycin post | #8 |
| eye redness | #8 |
| noninfectious corneal | #8 |
| surface teros | #8 |
| oedema scores | #8 |
| controls brush | #8 |
| brush cytology | #8 |
| limbalbased conjunctival flap | #8 |
| expressions thought | #8 |
| ulcers detected | #8 |
| alterations allergic | #8 |
| corneal epithelial lesions | #8 |
| corneal scores | #8 |
| asia cats | #8 |
| tnfalpha eosinophils | #8 |
| trabeculectomy amniotic | #8 |
| blinking body | #8 |
| reductase cataract | #9 |
| acid goblet | #9 |
| crth2 expression eosinophils | #9 |
| subjective ocular | #9 |
| fluorescein rose | #9 |
| hyperemia iop | #9 |
| genes cxc | #9 |
| level pollutants | #9 |
| untreated asian | #9 |
| injection edema | #9 |
| shield ulcers | #9 |
| implantation 1cu | #9 |
| prospective study tacrolimus | #9 |
| vital staining scores | #9 |
| measurements vital | #9 |
| tnfalpha fibroblasts | #9 |
| cys eye | #9 |
| cobblestone papillae | #9 |
| design eyelid | #9 |
| stress staining | #9 |
| patients tacrolimus treatment | #9 |
| smart eye | #9 |
| operatedon eye | #9 |
| foreign body sensation | #9 |
| diagnosis conjunctivitis | #9 |
| concentration tears | #9 |
| sensitivity confocal | #9 |
| specular microscopic evaluation | #9 |
| pretreatment docosahexaenoic | #9 |
| sensitivity conjunctival | #9 |
| differ allergic | #9 |
| symptoms allergic conjunctivitis | #9 |
| eye normal subjects | #9 |
| pathogen allergic | #9 |
| diseases conjunctivitis | #9 |
| sufficient examination | #9 |
| pollution conjunctivitis | #9 |
| supply superior | #9 |
| conjunctivitis cases | #9 |
| tears thermography | #9 |
| eye grade | #9 |
| hel 4 | #9 |
| pilocarpine tablets | #9 |
| observed obstructive | #9 |
| excision intraoperative | #9 |
| prevalence weather | #9 |
| ono2235 | #9 |
| superior limbic | #9 |
| conjunctival fibroblast | #9 |
| vital stainings | #9 |
| inflammation steroidal | #9 |
| prevalence vkc | #9 |
| mmc recurrence | #9 |
| severity corneal | #9 |
| wash solution | #9 |
| fatigue dry | #9 |
| 0001 schirmer | #9 |
| glaucoma younger age | #9 |
| received preserved | #9 |
| tear level | #9 |
| elisa tears | #9 |
| blood level tacrolimus | #9 |
| clinical ocular findings | #9 |
| tacrolimus treating | #9 |
| cases conjunctivitis | #9 |
| sio2 pbs | #9 |
| histocytological study | #9 |
| tacrolimus 95 | #9 |
| meibomian gland obstruction | #10 |
| cytometry il4 | #10 |
| crth2 chemotaxis | #10 |
| incubated il4 | #10 |
| allergic ocular | #10 |
| conjunctival edema | #10 |
| tear cytology | #10 |
| par2 mast | #10 |
| layer alterations | #10 |
| lacrimal puncta | #10 |
| ophthalmic adolescent | #10 |
| aged conjunctivitis | #10 |
| resection regrowth | #10 |
| staining oral | #10 |
| cornea eosinophils | #10 |
| conjunctivitis spring | #10 |
| topical cyclosporine patients | #10 |
| visante optical | #10 |
| bengal stainings | #10 |
| lower tmh | #10 |
| humans mucin | #10 |
| shield ulcer | #10 |
| conjunctivitis atopic | #10 |
| conjunctivitis japan | #10 |
| status conjunctival | #10 |
| levels tears | #10 |
| drugs conjunctival | #10 |
| vmr values | #10 |
| measuring tear | #10 |
| complain | #10 |
| assessed conjunctival | #10 |
| treatment vkc | #10 |
| compared eyes | #10 |
| punctal occlusion | #10 |
| substance tears | #10 |
| subbasal stromal | #10 |
| tears 10 | #10 |
| produced conjunctival | #10 |
| eye clinically | #10 |
| total tear ige | #10 |
| nonallergic conjunctivitis | #10 |
| icam1 tnfalpha | #10 |
| eye surface | #10 |
| measurement strip | #10 |
| muc5ac muc16 | #10 |
| underwent slit | #10 |
| diagnosis dry eye | #10 |
| functions dry | #10 |
| scale tear | #10 |
| allergic bronchitis | #10 |
| improvement tear | #10 |
| leupeptin benzamidine | #10 |
| conjunctivitis histamine | #10 |
| proliferation conjunctival | #10 |
| evaluation atopic | #10 |
| muc16 muc5ac | #10 |
| central graft | #10 |
| patients ulcers | #10 |
| insufficient local | #10 |
| chemokines cxc chemokines | #10 |
| humans conjunctival | #10 |
| laminin actins | #10 |
| staining brush | #10 |
| iop hyperemia | #10 |
| sensation ocular | #10 |
| allergic conjunctivitis spring | #10 |
| eye infrared | #10 |
| lamp microscope | #11 |
| 1 month reduction | #11 |
| eosinophils prostaglandin | #11 |
| sensation tear | #11 |
| patient atopic | #11 |
| methods conjunctival | #11 |
| cytometry oligonucleotide | #11 |
| interleukin4 male | #11 |
| antivcaigg | #11 |
| ophthalmic solution | #11 |
| higher muc1 | #11 |
| test tear | #11 |
| landolt visual | #11 |
| smart eye camera | #11 |
| drop artificial | #11 |
| vkc adolescent | #11 |
| schirmer1 test | #11 |
| sensation staining | #11 |
| association outpatient | #11 |
| palpebral bulbar conjunctiva | #11 |
| levocabastine hydrochloride | #11 |
| vkc normal | #11 |
| surgery 13 eyes | #11 |
| amniotic membrane patch | #11 |
| prevalence dry eye | #11 |
| vkc | #11 |
| disease edition | #11 |
| initiation tacrolimus | #11 |
| anesthesia strabismus | #11 |
| vmr fva | #11 |
| keratitis observed | #11 |
| therapy conjunctivitis | #11 |
| purpose metaplasia | #11 |
| tears conjunctival | #11 |
| common conjunctival | #11 |
| vernal | #11 |
| vcam1 tnfalpha | #11 |
| elicited statistically | #11 |
| fibroblasts pathogenesis | #11 |
| genes corneal | #11 |
| count conjunctivitis | #11 |
| elisa il4 | #11 |
| cooling operation | #11 |
| function ocular | #11 |
| matched dry | #11 |
| diagnosis allergic | #11 |
| preserved artificial | #11 |
| coherence dry | #11 |
| hel hne | #11 |
| elasticity treatment | #11 |
| weeks papillary | #11 |
| keratoconjunctivitis patients | #12 |
| damage height | #12 |
| 1cu accommodating | #12 |
| biomarker allergic | #12 |
| fva visual | #12 |
| surface diabetic | #12 |
| highspeed highresolution | #12 |
| selected severity | #12 |
| mmhg elevation | #12 |
| radiography tears | #12 |
| mgd controls | #12 |
| fluorescein scores | #12 |
| microscopy efficient | #12 |
| cornea density | #12 |
| tears conjunctivitis | #12 |
| density acinar | #12 |
| fva vmr | #12 |
| receptor crth2 | #12 |
| 001 specimens | #12 |
| drugs pge2 | #12 |
| acids chemokine | #12 |
| corneal shield | #12 |
| leupeptins mast | #12 |
| severe binocular | #12 |
| extracts pollens | #12 |
| projects tears | #12 |
| expression 8 genes | #12 |
| ulcers squamous | #12 |
| coated lactoferrin | #12 |
| findings conjunctival | #12 |
| patients sac | #12 |
| lacrimal punctal | #12 |
| supratarsal injection | #12 |
| density muc5ac | #12 |
| specimens eyes | #12 |
| 1cu iol | #12 |
| iop glucocorticoids humans | #12 |
| iop younger | #12 |
| corneal aesthesiometry | #12 |
| 1821 subjects | #12 |
| conjunctival injection | #12 |
| immunologic rejection | #12 |
| pemirolast potassium | #12 |
| dermatitis tacrolimus | #12 |
| eye diagnosed | #12 |
| 002 ophthalmic | #12 |
| appearance atopic | #12 |
| controls antibody titers | #12 |
| conventional slit | #12 |
| ccl11 conjunctiva | #12 |
| keratoplasty glaucoma | #12 |
| levocabastine patients | #12 |
| glaucoma keratoplasty | #13 |
| week corneal | #13 |
| inflammation tear | #13 |
| remodeling relevant | #13 |
| objective signs | #13 |
| time fluorescein | #13 |
| conclusions ocular | #13 |
| aged disposable | #13 |
| epithelial disease | #13 |
| anterior segment photography | #13 |
| suspensions tacrolimus | #13 |
| months healed | #13 |
| conjunctival oedema | #13 |
| temperature cataract | #13 |
| tear hel | #13 |
| specimens levels | #13 |
| interferometry tear | #13 |
| topical cyclosporine treatment | #13 |
| syndrome reactivation | #13 |
| ulcers corneal | #13 |
| outcomes 01 | #13 |
| papillary samples | #13 |
| upper tarsal | #13 |
| corneal complications | #13 |
| improvement vital | #13 |
| treatment allergic conjunctivitis | #13 |
| 5ac ophthalmic | #13 |
| schirmers test values | #13 |
| sd105 | #13 |
| coherence viscosupplements | #13 |
| cell flare | #13 |
| chemokines stimulation | #13 |
| bengal fluorescein | #13 |
| glaucoma younger | #13 |
| compared postsurgical | #13 |
| blood levels tacrolimus | #13 |
| tear functions | #13 |
| applied operation | #13 |
| called giant | #13 |
| japan keratoconjunctivitis | #13 |
| fluorometholone fml | #13 |
| keratocytes incubated | #13 |
| vmr measurements | #13 |
| scraped samples | #13 |
| dry eye examination | #13 |
| stability vital | #13 |
| thirty eyes | #13 |
| symptoms conjunctival | #13 |
| protein conjunctival | #13 |
| conjunctivitis background | #14 |
| density tear | #14 |
| fungi adolescent | #14 |
| flare count | #14 |
| benzamidines blotting | #14 |
| epithelial muc5ac | #14 |
| blinking patients | #14 |
| dry eye controls | #14 |
| higher allergic | #14 |
| proliferative lesion | #14 |
| factors conjunctivitis | #14 |
| fluorometholone humans | #14 |
| schirmer1 | #14 |
| fibroblast damage | #14 |
| occlusion dry | #14 |
| visits allergic | #14 |
| functions corneal | #14 |
| conjunctival allergen challenge | #14 |
| secrete mediators | #14 |
| clinical corneal | #14 |
| solutions retrospective | #14 |
| 14 flare | #14 |
| mcfg treatment | #14 |
| test rose | #14 |
| clinically allergic | #14 |
| eyes 002 | #14 |
| bf 01 | #14 |
| radioimmunoassay tears | #14 |
| vehicle eye | #14 |
| conjunctival muc5ac | #14 |
| conjunctivitis vernal | #14 |
| pilocarpine effective | #14 |
| conjunctival impression | #14 |
| cornea endophthalmitis | #14 |
| tranilast anti | #15 |
| damaged fibroblasts | #15 |
| giant papillary | #15 |
| complications height | #15 |
| adherence fibroblasts | #15 |
| mmc female follow | #15 |
| steroidal cornea | #15 |
| occlusion oct | #15 |
| rtpcr cytometry | #15 |
| ige ecp | #15 |
| ocular surface mucins | #15 |
| ocular itching | #15 |
| evaluation conjunctival | #15 |
| correlation tear | #15 |
| examined existence | #15 |
| superior conjunctiva | #15 |
| eye drop treatment | #15 |
| bromobenzenes child | #15 |
| basal tear secretion | #15 |
| complications mmc | #15 |
| mucous discharge | #15 |
| blepharitis conjunctivitis | #15 |
| diseases 2020 | #15 |
| corneal recurrence | #15 |
| surface vital | #15 |
| analysis par2 | #15 |
| improvement subjective symptoms | #15 |
| tmh values | #15 |
| patients vernal | #15 |
| improvement corneal | #15 |
| cytology brush | #15 |
| monitoring tear | #15 |
| olopatadine 01 | #15 |
| ulcer echinocandins | #15 |
| topical 01 | #15 |
| expression realtime pcr | #15 |
| ocular acrylic | #15 |
| ophthalmology tokyo | #15 |
| irritation scores | #15 |
| vkc methods | #15 |
| receptor pgd2 | #15 |
| investigated corneal | #15 |
| agents blepharitis | #15 |
| day bf | #15 |
| occlusion rose | #15 |
| firstline drug | #15 |
| bilateral conjunctivitis | #15 |
| effects benzalkonium | #15 |
| segment photography | #16 |
| patients vernal keratoconjunctivitis | #16 |
| safety 01 | #16 |
| controls papillary | #16 |
| eosinophils receptor | #16 |
| 2 conjunctival | #16 |
| ulcers positive | #16 |
| odds ratio remission | #16 |
| lacrimation | #16 |
| assessment conjunctival | #16 |
| dust allergic | #16 |
| hours visit | #16 |
| reduction goblet | #16 |
| female goblet | #16 |
| treatment eyelid | #16 |
| objective ocular | #16 |
| ari administration | #16 |
| total clinical scores | #16 |
| measurements tear | #16 |
| ige correlation | #16 |
| fungi odds | #16 |
| alpha ortho | #16 |
| temperature conjunctiva | #16 |
| expression eotaxin1 | #17 |
| inhibitor ari | #17 |
| betamethasone induced | #17 |
| signs ded | #17 |
| strip meniscometry | #17 |
| 20 normal patients | #17 |
| conjunctival samples | #17 |
| drops eyes | #17 |
| increased goblet cells | #17 |
| fibroblasts mcp1 | #17 |
| age dry | #17 |
| muc16 mrna | #17 |
| fibroblasts damaged | #17 |
| corneal sensation | #17 |
| initiation objective | #17 |
| 13 females age | #17 |
| analyzed 005 | #17 |
| evaluation inflammatory | #17 |
| warmer treatment | #17 |
| clearance corneal | #17 |
| sclera trabeculectomy | #17 |
| inflammation blotting | #17 |
| staining muc1 | #17 |
| ocular allergic inflammation | #17 |
| eyes schirmer | #17 |
| agents cedrus | #17 |
| wear soft | #17 |
| meniscometry | #17 |
| ceramide gel | #17 |
| cd45 inflammatory | #18 |
| bengal sjogren | #18 |
| tnfα inflammatory response | #18 |
| rantes response | #18 |
| obstructive dysfunction | #18 |
| cytology decrease | #18 |
| groups spt | #18 |
| concentrations corneal | #18 |
| tear function | #18 |
| technique glaucoma | #18 |
| dibenzazepines dibenzoxepins | #18 |
| cytology corneal | #18 |
| trabeculectomy glaucoma | #18 |
| 30 ige | #18 |
| male ophthalmic solutions | #18 |
| pollen fungi | #18 |
| higher tears | #18 |
| lower eyes | #18 |
| ulcers compared | #18 |
| studies rose | #18 |
| intraoperative 002 | #18 |
| conclusion ocular | #18 |
| differentiation inflammatory cells | #18 |
| test tears | #18 |
| types dry eye | #18 |
| correlation clinical signs | #18 |
| fibroblasts giant | #18 |
| evaluation tear | #18 |
| tear evaporation rate | #18 |
| ulceration subjects | #18 |
| ocular surface status | #18 |
| noncl wearers | #18 |
| inflammation lenses | #18 |
| associations level | #18 |
| decrease ocular | #18 |
| induce corneal | #18 |
| complete staining | #18 |
| sma performed | #19 |
| outpatient attendance | #19 |
| 3 severe | #19 |
| eosinophils adhered | #19 |
| inflammatory cells patients | #19 |
| temperature artificial | #19 |
| 1151 years | #19 |
| human conjunctival | #19 |
| seldi proteinchip | #19 |
| conjunctivitis topical | #19 |
| effective tacrolimus | #19 |
| early efficacy | #19 |
| sodium 01 | #19 |
| periostin biomarker | #19 |
| beta1 il1beta | #19 |
| aged cautery | #19 |
| prospective study eyes | #19 |
| evaluated infrared | #19 |
| vernal keratoconjunctivitis | #19 |
| dha pretreatment | #19 |
| microscopy scans | #19 |
| mitomycin ophthalmologic | #19 |
| staining scores | #19 |
| subjects underwent | #19 |
| aged ophthalmic | #19 |
| total signs | #19 |
| limbal allograft | #19 |
| steroid female | #19 |
| measurements visante | #19 |
| operation applied | #19 |
| ige tear | #19 |
| seldi analysis | #19 |
| explain pathogenesis | #20 |
| treated 01 | #20 |
| improvements ocular | #20 |
| conjunctivitis caused | #20 |
| tears corneal | #20 |
| symptoms allergic | #20 |
| pollen association | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| proteins tears | #20 |
| ulcers cell | #20 |
| conclusion tacrolimus | #20 |
| echinocandins eye | #20 |
| conjunctivitis primary | #20 |
| summarized based | #20 |
| plaques graded | #20 |
| cytology upper | #20 |
| evaluate noninferiority | #20 |
| common ocular disorders | #20 |
| height tmh | #20 |
| bilateral agerelated cataract | #20 |
| lower dry | #20 |
| surface findings | #20 |
| allergic female humans | #20 |
| xerophthalmia adolescent | #20 |
| decreased conjunctival | #20 |
| persistent epithelial defect | #20 |
| corneal impression | #20 |
| mucin alterations | #20 |
| patients strip | #20 |
| 022 pg | #20 |
| film lipid | #21 |
| conclusions topical | #21 |
| reaction tears | #21 |
| preventing corneal | #21 |
| fluorescence postoperative | #21 |
| eye control | #21 |
| induced topical | #21 |
| crth2 expressed | #21 |
| levels hel | #21 |
| patients cedar | #21 |
| surface mucin | #21 |
| eosinophils flow cytometry | #21 |
| acuity assessment | #21 |
| adhesion fibroblast | #21 |
| cornea clinical | #21 |
| lipid oxidative | #21 |
| methane nonmethane hydrocarbons | #21 |
| ocular symptoms signs | #21 |
| tears blood | #21 |
| cultured conjunctiva | #21 |
| ige groups | #21 |
| patients concomitant treatment | #21 |
| symptoms include | #21 |
| eye smaller | #21 |
| radiation thermometer | #21 |
| reduction topical | #21 |
| conjunctiva role | #21 |
| microscopy patients | #21 |
| keratoconjunctivitis atopic | #21 |
| peripheral blood eosinophils | #21 |
| haze photorefractive | #22 |
| flare anterior | #22 |
| serum periostin patients | #22 |
| 01 tacrolimus | #22 |
| types ocular | #22 |
| accommodation amplitude | #22 |
| therapies allergic | #22 |
| correlation humidity | #22 |
| epithelial lipid | #22 |
| muc5ac patients | #22 |
| 005 topical | #22 |
| fibroblasts anti | #22 |
| eyes nerve | #22 |
| fluorescein staining | #22 |
| mgd adult | #22 |
| negative lower | #22 |
| 01 severe | #23 |
| 215 ± | #23 |
| solution compared | #23 |
| cooling applied | #23 |
| corneal fluorescein | #23 |
| palpebral conjunctiva | #23 |
| pge2 supernatants | #23 |
| diseases diclofenac | #23 |
| prospectively surgery | #23 |
| layer interferometry | #23 |
| score deqs | #23 |
| tests adenovirus | #23 |
| solution corneal | #23 |
| subjects squamous | #23 |
| tear dynamics | #23 |
| hrt confocal | #23 |
| disease atopic | #23 |
| lamp examinations | #23 |
| labeling tears | #23 |
| blood concentration tacrolimus | #23 |
| patients topical steroids | #23 |
| preschool conjunctivitis | #23 |
| function mucin | #23 |
| il4 tnf | #23 |
| 5 females | #23 |
| patients tacrolimus ointment | #24 |
| signs serum | #24 |
| interleukin4 oligonucleotide | #24 |
| bengal tears | #24 |
| dermatitis improved | #24 |
| control tear | #24 |
| layer tear | #24 |
| edema drug | #24 |
| 27yearold male patient | #24 |
| diseases web | #24 |
| conjunctiva diabetes | #24 |
| cell meter | #24 |
| local allergic reaction | #24 |
| vkc patients | #24 |
| vital staining | #24 |
| samples conjunctival | #24 |
| histamine development | #24 |
| tokyo dental | #24 |
| fungal corneal | #24 |
| warming device | #24 |
| ocular allergies | #24 |
| surface tear | #24 |
| formation allergic | #24 |
| tarsal conjunctiva | #24 |
| rsv rtpcr | #25 |
| rtpcr rsv | #25 |
| corneal plaques | #25 |
| bengal scores | #25 |
| staining goblet | #25 |
| steroid eye | #25 |
| vkc compared | #25 |
| level tears | #25 |
| antigen conjunctiva | #25 |
| protein rtpcr | #25 |
| dynamics tear | #25 |
| 0001 dry | #25 |
| schedule eosinophil | #25 |
| density squamous | #25 |
| vcam1 activated | #25 |
| superficial cells | #25 |
| eyes epithelial | #25 |
| confocal prospective | #25 |
| patients atopic diseases | #25 |
| atopic eosinophils humans | #25 |
| slitlamp examinations | #25 |
| symptoms itching | #26 |
| postkeratoplasty glaucoma | #26 |
| dmem f12 medium | #26 |
| human α defensin | #26 |
| slit lamp examinations | #26 |
| diseases ambient | #26 |
| 100 nylon | #26 |
| solutions corneal | #26 |
| specific ige positivity | #26 |
| treatment meibomian | #26 |
| 01 topical | #26 |
| rapid epithelialization | #26 |
| actins collagen | #26 |
| aureus detected | #26 |
| eyes topical | #26 |
| wheal diameter | #26 |
| statistical decrease | #26 |
| conclusions improvement | #26 |
| corneal ulcers | #26 |
| damage adhesion | #26 |
| conjunctival inflammation | #26 |
| subjects measuring | #26 |
| acinar unit | #26 |
| smallincision cataract surgery | #26 |
| keratoconjunctivitis caused | #26 |
| conjunctivitis | #26 |
| lnfs | #26 |
| adhered fibroblasts | #26 |
| correlated corneal | #26 |
| level il4 | #26 |
| tbut tear | #26 |
| singletreatment groups | #26 |
| 005 immunoreactive | #26 |
| antibodies brush | #27 |
| 005 symptoms | #27 |
| child cytological | #27 |
| factor exacerbation | #27 |
| lymphocytes specimens | #27 |
| eosinophils fibroblasts | #27 |
| cytometry chemotaxis | #27 |
| prescribed topical | #27 |
| interleukin4 polymerase | #27 |
| epinastine | #27 |
| reaction sensation | #27 |
| therapy conjunctiva | #27 |
| tear ocular | #27 |
| associations prevalence | #27 |
| conjunctival epithelial | #27 |
| 01 cyclosporine | #27 |
| alpha eosinophils | #27 |
| oct prospective | #27 |
| density subbasal | #27 |
| underwent immunohistochemical | #28 |
| papillae patients | #28 |
| diseases proliferative | #28 |
| provide relief | #28 |
| prevalence allergic diseases | #28 |
| ophthalmic | #28 |
| 4 5ac | #28 |
| conjunctiva dexamethasone | #28 |
| chemotactic activity eosinophils | #28 |
| giant papillae | #28 |
| conjunctival epithelial cells | #28 |
| assay eosinophils | #28 |
| solutions ophthalmologic | #28 |
| corneal ulceration | #28 |
| assessment tear | #28 |
| stress atopic | #28 |
| severe ocular | #28 |
| objective scores | #28 |
| eosinophil adherence | #28 |
| 2 iol | #28 |
| corneal vivo | #28 |
| il13 il1beta | #28 |
| inhibited tranilast | #29 |
| cys treatment | #29 |
| sac compared | #29 |
| conjunctiva dose | #29 |
| allergic regulation | #29 |
| performed morphometric | #29 |
| thermography adolescent | #29 |
| corneal conjunctival | #29 |
| rosebengal | #29 |
| ketotifen fumarate | #29 |
| scores schirmer | #29 |
| aged thermography | #29 |
| disease periostin | #29 |
| studies conjunctivitis | #29 |
| numbers inflammatory | #29 |
| 5ac mucins | #29 |
| flare cell | #29 |
| eye mask | #29 |
| inhibitors pollen | #30 |
| mucins ophthalmic | #30 |
| ocular surface alterations | #30 |
| dermatitis efficacy | #30 |
| palpebral | #30 |
| tear ige | #30 |
| common adverse reaction | #30 |
| conjunctivitis humans | #30 |
| fibroblasts protease | #30 |
| regrowth observed | #30 |
| redness eye | #30 |
| effective artificial | #30 |
| infection conjunctival | #30 |
| symptoms accompanying | #30 |
| tear serum | #30 |
| conjunctivitis patients | #30 |
| recruitment day | #30 |
| specificity tears | #30 |
| minutes visit | #30 |
| syndromes equipment | #30 |
| il2r serum | #30 |
| atopic diagnostic | #30 |
| expressed crth2 | #30 |
| conjunctiva cells | #30 |
| eye common | #30 |
| dermatitis purpose | #31 |
| levels july | #31 |
| properties tears | #31 |
| fibroblasts pcr | #31 |
| meibomian gland secretion | #31 |
| disease summarized | #31 |
| pathogenesis corneal | #31 |
| scores corneal | #31 |
| vegf cultured | #31 |
| atopic 10 | #31 |
| neutrophils severity | #31 |
| hel levels | #31 |
| inflammation atopic | #31 |
| acuity fva | #31 |
| expressed eosinophils | #31 |
| epithelial mucins | #31 |
| ige negative | #31 |
| schirmer scores | #31 |
| combinations eosinophils | #31 |
| worse observed | #31 |
| deqs | #32 |
| tear meniscus height | #32 |
| limbus cornea | #32 |
| conjunctival cells | #32 |
| analysis tears | #32 |
| substantial interrater agreement | #32 |
| tgfbeta1 il1beta | #32 |
| prostaglandin cell | #32 |
| reduced steroid | #32 |
| diagnosed dry | #32 |
| signs improved | #32 |
| western blotting effects | #32 |
| expressibility | #32 |
| eye sjögren | #32 |
| keratoconjunctivitis | #32 |
| sign scores | #32 |
| schirmer test values | #32 |
| count prostaglandin | #33 |
| ige histamine | #33 |
| film break | #33 |
| immunoglobulin interferometry | #33 |
| muc 1 | #33 |
| levocabastine | #33 |
| signs evaluated | #33 |
| conclusions confocal | #33 |
| seasonal young | #33 |
| haze score | #33 |
| 4 grades | #33 |
| iop induced | #33 |
| edema correlated | #33 |
| allergic double | #33 |
| numbers quantitative | #33 |
| atopic skin disease | #33 |
| visante | #33 |
| treatment mgd | #34 |
| eyes corneal | #34 |
| clinical signs patients | #34 |
| eye 10 | #34 |
| proteinchip array | #34 |
| alpha fibroblasts | #34 |
| il1beta tgfbeta1 | #34 |
| fluorometholone glucocorticoids | #34 |
| fibroblasts purpose | #34 |
| bengal staining | #34 |
| intraocular pressure surgery | #34 |
| conjunctiva cytokines | #34 |
| therapy histamine | #34 |
| 10 objective | #34 |
| 01 effective | #34 |
| interrater reproducibility | #35 |
| tear stability | #35 |
| virus capsid antigen | #35 |
| objective symptoms | #35 |
| mucins prospective | #35 |
| 6 months conclusion | #35 |
| cyclosporine cys | #35 |
| adult asthenopia | #35 |
| eye 20 | #35 |
| hypertension tacrolimus | #35 |
| diseases eosinophil | #36 |
| differential dry | #36 |
| anterior scleritis | #36 |
| vdt users | #36 |
| ocular surface inflammation | #36 |
| humans keratoconjunctivitis | #36 |
| functional visual acuity | #36 |
| tear samples | #36 |
| eyes acrysof | #36 |
| schirmer 1 | #36 |
| measured tear | #36 |
| tear clearance | #36 |
| resection 005 | #36 |
| efficacy groups | #36 |
| severe allergic | #36 |
| eyelid skin | #37 |
| conducted compliance | #37 |
| wellrecognized risk | #37 |
| tears tumor | #37 |
| laser flarecell meter | #37 |
| tacrolimus 12 | #37 |
| schirmer 1 test | #37 |
| induced iop | #37 |
| 002 mmc | #37 |
| tenon anesthesia | #37 |
| delefilcon | #37 |
| scleritis episcleritis | #37 |
| recurrence corneal | #37 |
| contact lens surface | #37 |
| oct effective | #37 |
| pemirolast | #38 |
| aged olopatadine | #38 |
| 002 mitomycin | #38 |
| cac japanese | #38 |
| allergic cromolyn | #38 |
| device eye | #38 |
| post cataract | #38 |
| exhibited correlation | #38 |
| gland lipid | #38 |
| phacoemulsification implantation | #38 |
| cells conjunctiva | #39 |
| tests diagnostic accuracy | #39 |
| response pretreatment | #39 |
| 0001 specimens | #39 |
| 005 oct | #39 |
| atopic dry | #39 |
| patients dry eye | #39 |
| degree 20 | #39 |
| accommodating intraocular | #39 |
| solutions patient | #39 |
| cyclosporine dry | #39 |
| tears eye | #39 |
| conjunctiva limbus | #39 |
| infiltration corneal | #39 |
| acid chemokine | #40 |
| subjects specimens | #40 |
| decreased inflammation | #40 |
| pharmacology clinical efficacy | #40 |
| ulcers control | #40 |
| biomarkers conjunctiva | #40 |
| eye patients | #40 |
| drops corneal | #40 |
| endothelial rejection | #40 |
| tmh | #40 |
| samples eyes | #40 |
| conjunctivitis gpc | #41 |
| ecp concentrations | #41 |
| il1beta vegf | #41 |
| vegf il1beta | #41 |
| treatment dry | #41 |
| homologous visual | #41 |
| α pge2 | #41 |
| eyes superior | #41 |
| epitheliopathy | #41 |
| stimulate vascular | #41 |
| treated topical | #41 |
| pollution severe | #41 |
| corneal epithelia | #42 |
| scans underwent | #42 |
| break time | #42 |
| efficient noninvasive | #42 |
| october july | #42 |
| allergens conjunctivitis | #42 |
| day eye | #42 |
| instability decreased | #43 |
| eyelid edema | #43 |
| cytology revealed | #43 |
| diseases 2017 | #43 |
| conjunctival hyperemia | #43 |
| rollable | #43 |
| hydrocarbons data | #43 |
| microscopy central | #43 |
| limbus corneal | #43 |
| keratolimbal | #43 |
| surface years | #43 |
| meniscus treatment | #43 |
| revised 2010 | #43 |
| il1beta il4 | #44 |
| subjective symptom | #44 |
| tryptase par2 | #44 |
| collagens fibronectin | #44 |
| tear meniscus | #44 |
| cautery female | #44 |
| tacrolimus treatment | #44 |
| elasticity patients | #44 |
| oct assessment | #44 |
| epithelial defect | #44 |
| eye 0001 | #44 |
| agents keratoconjunctivitis | #44 |
| patients rhinoconjunctivitis | #44 |
| abovementioned drugs | #44 |
| activated il4 | #44 |
| formation corneal | #45 |
| surgery uncorrected | #45 |
| users contact | #45 |
| metaplasia mucin | #45 |
| case corneal | #45 |
| superficial punctate keratitis | #45 |
| signs score | #45 |
| inflammation ocular surface | #45 |
| fibroblasts expression | #45 |
| rose bengal staining | #45 |
| body sensation | #45 |
| elevation iop | #45 |
| recruiting chemokines | #45 |
| micafungin mcfg | #45 |
| japan particulate | #45 |
| fourgrade scale | #45 |
| 24 seconds | #45 |
| adult chemotaxis | #45 |
| bovine enteric | #45 |
| graded 3 | #45 |
| surface inflammation | #45 |
| laser microscopy | #45 |
| understanding ocular | #45 |
| correlation inflammation | #45 |
| topical tacrolimus treatment | #45 |
| metaplasia grade | #45 |
| fibroblasts eosinophils | #45 |
| tryptases regulation | #46 |
| staining conjunctival | #46 |
| il13 serum | #46 |
| status ocular | #46 |
| conjunctival | #46 |
| fluorometholone | #46 |
| 17 japanese patients | #46 |
| posttreatment findings | #46 |
| seconds controls | #46 |
| suspension effective | #46 |
| surface disease | #46 |
| efficacy combined therapy | #46 |
| efficacy 01 | #46 |
| graticule | #46 |
| staining inflammatory | #46 |
| corneal cells | #46 |
| patients 01 | #47 |
| purpose efficacy | #47 |
| suspension 4 | #47 |
| visante oct | #47 |
| positive muc5ac | #47 |
| diameter plant | #47 |
| allergic female histamine | #47 |
| rate ocular | #47 |
| ulcer score | #47 |
| blood level | #47 |
| brush cytology specimens | #48 |
| implantation acrysof | #48 |
| stromal nerve | #48 |
| muc5ac mrna | #48 |
| sac patients | #48 |
| complications corneal | #48 |
| eyes month | #48 |
| stimulation chemokine | #48 |
| eyelid warming | #48 |
| dexamethasone anti | #48 |
| enhanced benefits | #48 |
| cyclosporine ophthalmic | #48 |
| objective findings | #49 |
| tacrolimus female | #49 |
| keratocytes fibroblasts | #49 |
| eosinophils epithelium | #49 |
| expression crth2 | #49 |
| ocular signs | #49 |
| cxc chemokine genes | #49 |
| concentrations tears | #49 |
| 1cu | #49 |
| visits air | #49 |
| adult ca125 | #49 |
| male tears | #49 |
| trabeculectomy eyes | #49 |
| fibroblasts incubated | #49 |
| inflammation conjunctiva | #50 |
| decreased tear | #50 |
| total severity score | #50 |
| measuring corneal | #50 |
| patient eyes | #50 |
| trabeculectomy mitomycin | #50 |
| ulcers purpose | #50 |
| test ocular | #50 |
| aged blinking | #50 |
| 4 normal controls | #50 |
| disposable soft | #50 |
| dyes fluorophotometry | #50 |
| schirmers test | #50 |
| meniscus height | #50 |
| lenses scls | #51 |
| reduction score | #51 |
| effects docosahexaenoic acid | #51 |
| inflammation cataract | #51 |
| cells brush | #51 |
| members japan | #51 |
| scls | #51 |
| periostin patients | #51 |
| crth2 expression | #51 |
| markers atopic | #51 |
| ocular surface cells | #51 |
| diagnosis dry | #51 |
| tears tomography | #52 |
| month initiation | #52 |
| stability corneal | #52 |
| inflammation decline | #52 |
| severity objective | #52 |
| examination parameters | #52 |
| eyelid margins | #52 |
| biomarker diseases | #52 |
| eye normal | #52 |
| atopic groups | #52 |
| reaction vehicle | #52 |
| pcr tgf | #52 |
| stromal nerves | #53 |
| acuity values | #53 |
| differential eosinophil | #53 |
| bromfenac | #53 |
| vegf protein secretion | #54 |
| presence rsv | #54 |
| chloride bak | #54 |
| limbic keratoconjunctivitis | #54 |
| obstructive mgd | #54 |
| 005 month | #54 |
| suspension treatment | #54 |
| oxidation adolescent | #54 |
| scores tear | #54 |
| lacrimal glands | #54 |
| conjunctiva drug | #55 |
| combinedtreatment | #55 |
| ocular signs symptoms | #55 |
| atopic enterotoxins | #55 |
| antagonists allergic | #55 |
| local cytokine production | #55 |
| aged pollen | #55 |
| adult conjunctivitis | #55 |
| surface clinical | #55 |
| epithelial cells expression | #55 |
| specular microscopic | #56 |
| mechanism giant | #56 |
| pain photophobia | #56 |
| plant pollens | #56 |
| 3 dry | #56 |
| topical adolescent | #56 |
| mucin2 mucin4 | #56 |
| ded adult | #56 |
| film ocular | #56 |
| allergies adolescent | #56 |
| dysfunction atopic | #56 |
| mucin layer | #56 |
| solution placebo | #56 |
| eosinophil cationic | #56 |
| cornea cyclooxygenase | #56 |
| atopic patients | #56 |
| humans interleukin4 | #57 |
| chemotactic responses | #57 |
| insensible administration | #57 |
| penetrating limbus | #57 |
| giant papillary conjunctivitis | #57 |
| inflammation pge2 | #57 |
| accommodating iol | #57 |
| alpha defensins | #58 |
| staining tear | #58 |
| objective sign | #58 |
| maximum blood concentration | #58 |
| papilla formation | #58 |
| seventyeight eyes | #58 |
| schiff staining | #58 |
| drop treatment | #58 |
| pm25 prevalence | #59 |
| findings criteria | #59 |
| intraoperative mitomycin | #59 |
| tear instability | #59 |
| disease eyes | #59 |
| type allergic | #59 |
| mmc 2 | #60 |
| daily disposable | #60 |
| pcr severe | #60 |
| compared 0001 | #60 |
| signs severe | #60 |
| tacrolimus ointment treatment | #60 |
| evaluation items | #60 |
| release inhibitor | #60 |
| diabetic corneal | #60 |
| syndromes female | #60 |
| correlation patients | #61 |
| thermography adult | #61 |
| nonsteroidal blotting | #61 |
| punctal | #61 |
| specimens histopathologic | #62 |
| values tended | #62 |
| combination epithelium | #62 |
| eotaxin1 expression | #62 |
| expression eyes | #62 |
| allergen mediated | #62 |
| eyes 16 | #62 |
| amplitude accommodation | #62 |
| total clinical | #62 |
| prostaglandin patients | #62 |
| patient corneal | #63 |
| conjunctiva patients | #63 |
| hypersensitivity japan | #63 |
| corneal erosion | #63 |
| corneal stem | #63 |
| micafungin treatment | #63 |
| ulcer endophthalmitis | #63 |
| il4 role | #63 |
| sac age | #63 |
| oral pilocarpine | #63 |
| chamber body | #63 |
| il4 culture | #64 |
| evaluation corneal | #64 |
| cornea dry | #64 |
| radioimmunoassay respiratory | #64 |
| factor allergic | #64 |
| eye adolescent | #64 |
| density inflammatory | #64 |
| positive mucin | #64 |
| dexamethasone production | #64 |
| conclusions corneal | #65 |
| dust house | #65 |
| microscope methods | #65 |
| viral radioimmunoassay | #65 |
| tears biomarkers | #65 |
| mucins rna | #65 |
| live rsv | #65 |
| treatment immunosuppressive agents | #66 |
| surface epithelial | #66 |
| layer speed | #66 |
| cases atopic | #66 |
| diagnosis therapies | #66 |
| period oral | #67 |
| persistent epithelial | #67 |
| female fluorophotometry | #67 |
| effects 01 | #67 |
| agents keratoplasty | #67 |
| 003 treatment | #67 |
| cyclosporine eye | #67 |
| time vital | #68 |
| eye dry | #68 |
| housedust | #68 |
| ointment treatment | #68 |
| glaucoma graft | #69 |
| counter drugs | #69 |
| ophthalmic solutions | #69 |
| occlusion 005 | #69 |
| fibroblasts corneal | #69 |
| aged tears | #69 |
| patients eosinophils | #69 |
| fibroblasts examined | #69 |
| crth2 pgd2 | #70 |
| 1436 patients | #70 |
| values rose | #70 |
| 22 eyes | #70 |
| crth2 receptor | #70 |
| schirmer test | #70 |
| visit 4 | #70 |
| rhinoconjunctivitis allergic | #70 |
| dust 20 | #71 |
| drops treatment | #71 |
| allergic dermatitis | #71 |
| factors tears | #71 |
| lenses dry | #71 |
| bulbar conjunctiva | #72 |
| glaucoma trabeculectomy | #72 |
| ige eosinophil | #72 |
| tear production | #72 |
| 16 eyes | #72 |
| liquid conjunctiva | #73 |
| fluorophotometry humans | #73 |
| punctate keratopathy | #73 |
| surface mucins | #73 |
| immunosuppressive treatment patients | #73 |
| extraction conjunctiva | #73 |
| pollution prevalence | #73 |
| antiallergic agent | #73 |
| epithelial structure | #73 |
| pyridines pyrimidinones | #73 |
| fml | #73 |
| inflammatory cell numbers | #74 |
| mcfg | #74 |
| iol acrysof | #74 |
| evaluation dry | #74 |
| tacrolimus patients | #74 |
| eosinophils expressed | #74 |
| agents intraocular | #74 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| improved infrared | #75 |
| dust epidemiologic | #75 |
| pilocarpine prospective | #75 |
| completely controlled | #75 |
| 1 month baseline | #75 |
| laser flare | #75 |
| ccchemokine | #76 |
| guidelines allergic | #76 |
| agents interleukin4 | #76 |
| interleukin4 rna | #76 |
| ophthalmological elasticity | #77 |
| cytokines stimulate | #77 |
| cytology samples | #77 |
| vegf tgfbeta1 | #77 |
| surgery technique | #77 |
| signs treatment | #77 |
| cornea module | #77 |
| studies suspensions | #77 |
| excision recurrence | #77 |
| capilia | #77 |
| slight elongation | #77 |
| chemical mediator | #77 |
| lower tear | #77 |
| signs observed | #78 |
| japanese guideline | #78 |
| drops 1 | #78 |
| severity ocular | #78 |
| pollen compared | #78 |
| concomitant tacrolimus | #78 |
| concentration il2 | #78 |
| dry eye | #79 |
| ocular pain | #79 |
| glaucoma penetrating | #79 |
| allergic environmental | #79 |
| injection reduction | #79 |
| type allergy | #79 |
| permeability cornea | #79 |
| inhibitors leupeptin | #79 |
| effects corneal | #79 |
| extended wear | #79 |
| il4 ige | #79 |
| mediated par2 | #80 |
| assay epithelial | #80 |
| medications required | #80 |
| questionnaires tears | #80 |
| mgd patients | #80 |
| vegf concentration | #81 |
| decreased dry | #81 |
| antigens histamine | #81 |
| cytology performed | #82 |
| prostaglandin reverse | #82 |
| atopic dermatitis study | #82 |
| caused insufficient | #82 |
| acrysof iol | #82 |
| patients conjunctivitis | #82 |
| patients staphylococcus aureus | #83 |
| complications lenses | #83 |
| tear lipid | #83 |
| expression corneal | #83 |
| data tacrolimus | #83 |
| dental college | #83 |
| schirmer | #84 |
| correlation corneal | #84 |
| cytokines vegf | #84 |
| papillae | #84 |
| epithelium ocular | #84 |
| earlier published data | #84 |
| human reverse | #85 |
| combined penetrating | #85 |
| 18 pg | #85 |
| patients dry | #85 |
| 5 grades | #85 |
| hyperemia induced | #85 |
| scleritis patients | #85 |
| temperature patients | #85 |
| alterations basal | #85 |
| treatment odds ratio | #85 |
| inhibitors tryptases | #85 |
| pharmacologic intervention | #86 |
| acuity accommodation | #86 |
| edema scores | #86 |
| daily outpatient | #86 |
| patients eyelid | #86 |
| sligkv | #86 |
| discharge evaluated | #86 |
| 284 years | #86 |
| inflammation eye | #86 |
| tacrolimus reduced | #87 |
| detection limit assay | #87 |
| confocal ophthalmic | #87 |
| tacrolimus young | #87 |
| cells keratocytes | #88 |
| sclera surgical | #88 |
| tears | #88 |
| regulation muc5ac | #88 |
| daily weather conditions | #88 |
| disease conjunctiva | #88 |
| post keratoplasty | #88 |
| tears visual | #89 |
| findings severe | #89 |
| seasonal perennial | #89 |
| eyes 30 | #89 |
| assessment dry | #89 |
| tryptase inhibitors | #89 |
| early ocular | #90 |
| cytocentrifuge preparations | #90 |
| lower corneal | #90 |
| temperature cornea | #90 |
| decrease corneal | #90 |
| dressings chronic | #90 |
| months signs | #90 |
| glands microscopy | #90 |
| tears adult | #90 |
| film breakup | #91 |
| lenses extended | #91 |
| eye corneal | #92 |
| techniques trabeculectomy | #92 |
| exposure japan | #92 |
| laser cell | #92 |
| procedures phacoemulsification | #92 |
| preschool conjunctiva | #93 |
| eye cataract surgery | #93 |
| conjunctival specimens | #93 |
| regulation muc1 | #93 |
| treatment noninfectious | #93 |
| drug fibroblasts | #93 |
| tears administration | #93 |
| patients correlation | #93 |
| 005 complications | #93 |
| 7 visit | #93 |
| solutions tears | #93 |
| stromal corneal | #93 |
| exposure exhaust | #94 |
| pollution weather | #94 |
| classification pathogenesis | #94 |
| reaction physical | #94 |
| case allergic | #94 |
| pgd2 crth2 | #94 |
| relevant factor | #95 |
| eye higher | #95 |
| twentyeight eyes | #95 |
| eosinophils patients | #95 |
| induced pgd2 | #95 |
| studies tears | #95 |
| 128 eyes | #96 |
| study cyclosporine | #96 |
| protein eosinophilia | #96 |
| score objective | #96 |
| staining fluorescein | #96 |
| higher eyes | #96 |
| 1month treatment | #97 |
| treatment ecp | #97 |
| production pge2 | #97 |
| 4 alterations | #97 |
| cells hel | #97 |
| staining schirmer | #98 |
| eyes positive | #98 |
| eyes study | #98 |
| vdts | #98 |
| eye tear | #98 |
| meniscus patients | #98 |
| cytology evaluation | #99 |
| management ocular | #99 |
| japan post | #99 |
| surgery 6 months | #99 |
| pseudophakic patients | #99 |
| 005 recurrence | #99 |
| equivalent 4 | #99 |
| solution improved | #99 |
| cells severity | #100 |
| ulcer patient | #100 |
| local pattern | #100 |
| postoperatively statistically | #100 |
| conjunctiva corneal | #100 |
| confocal scanning | #100 |
| ointments tacrolimus | #100 |
| allergic atopic | #100 |
| terminals contact | #100 |
| corneal abnormalities | #100 |
| eyes 10 | #101 |
| fibroblasts 2 | #101 |
| pathogenesis atopic | #101 |
| pathogenesis allergic | #102 |
| agents conjunctivitis | #102 |
| effects tranilast | #102 |
| therapy conjunctival | #102 |
| severe atopic | #102 |
| keratolimbal allograft | #102 |
| disease classified | #102 |
| washing solution | #103 |
| subjective comfort | #103 |
| prevalence dry | #103 |
| mediated protease | #103 |
| chemotaxis experiments | #103 |
| values vital | #104 |
| topical cyclosporine | #104 |
| groups dry | #104 |
| tears young | #104 |
| syndrome epstein | #104 |
| topic premedication | #104 |
| differences ocular | #104 |
| patients bf | #104 |
| allergic cytokines | #104 |
| events scores | #104 |
| aged amnion | #105 |
| baseline initiation | #105 |
| role staphylococcal | #105 |
| inflammation diagnosis | #105 |
| wearing contact | #105 |
| conjunctival impression cytology | #105 |
| child conjunctival | #105 |
| adhesion fibroblasts | #106 |
| pressure keratoplasty | #106 |
| parameters ocular | #106 |
| 14 eyes | #106 |
| conjunctiva cornea | #106 |
| microscopy evaluation | #106 |
| eotaxin1 | #107 |
| corneal keratocytes | #107 |
| superficial punctate | #107 |
| patients ded | #107 |
| dry mouth symptoms | #108 |
| film instability | #108 |
| acuity acrylic | #108 |
| conjunctiva | #108 |
| induces chemotaxis | #108 |
| scores symptoms | #108 |
| levels radioimmunoassay | #108 |
| lipid layer | #108 |
| topical tacrolimus | #108 |
| resins aged | #108 |
| asian dust | #109 |
| effects dha | #109 |
| corneal inflammatory | #109 |
| tear evaporation | #109 |
| 4 dry | #109 |
| level tacrolimus | #109 |
| il4 human | #109 |
| eyes 9 | #110 |
| lacrimal salivary | #110 |
| japanese guidelines | #110 |
| controls inflammatory | #110 |
| steroids administration | #110 |
| increased evaporation | #110 |
| conjunctival epithelium | #110 |
| dysfunction mgd | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| anterior segment inflammation | #113 |
| strabismus surgery | #113 |
| solutions platelet | #113 |
| dibenzoxepins | #113 |
| papillary conjunctivitis | #113 |
| pcr rsv | #113 |
| lesions atopic | #114 |
| layer patients | #114 |
| eye irritation | #114 |
| incision cataract | #114 |
| grading scores | #114 |
| diagnosed allergic | #114 |
| goblet cell density | #115 |
| allergic eye | #115 |
| male mucin | #115 |
| 13 eyes | #115 |
| conjunctival cell | #115 |
| findings severity | #115 |
| seconds 0001 | #115 |
| sjögrens syndrome patients | #115 |
| cholinergic treatment | #115 |
| selective histamine | #116 |
| edition revised | #116 |
| cooling increased | #117 |
| ophthalmology prevalence | #117 |
| asia dust | #117 |
| patients seasonal | #117 |
| metaplasia mucins | #117 |
| samples stained | #117 |
| viscosupplements aged | #117 |
| effects docosahexaenoic | #118 |
| sag genes | #118 |
| molecule1 interleukin4 | #118 |
| generation pge2 | #118 |
| immunologic receptors prostaglandin | #118 |
| revealed higher | #119 |
| chemotaxis induced | #119 |
| topical steroids | #119 |
| skin elasticity | #119 |
| acuity distance | #119 |
| week 005 | #119 |
| iop observed | #119 |
| 39 mmhg | #119 |
| matter prevalence | #120 |
| syndromes epithelium | #120 |
| distance corrected | #121 |
| soft lenses | #121 |
| mitomycinc mmc | #121 |
| levels histamine | #121 |
| mitomycin ophthalmic | #121 |
| chronic allergic | #122 |
| artificial tear | #123 |
| adult conjunctiva | #123 |
| collagen conjunctiva | #123 |
| titers ebv | #123 |
| male ointments | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| conjunctival tissues | #125 |
| activity corneal | #125 |
| damage severe | #126 |
| month reduced | #126 |
| proteaseactivated receptor2 | #126 |
| patients atopic | #127 |
| subjects vivo | #127 |
| nerves studied | #127 |
| 05ng | #127 |
| soft contact lenses | #128 |
| 9 genes | #128 |
| gamma increase | #128 |
| fibroblast viability | #129 |
| 361 ± | #129 |
| elisa levels | #129 |
| acds | #129 |
| combination steroids | #129 |
| patients insignificant | #130 |
| functional visual | #130 |
| fva | #130 |
| antigen hladr | #131 |
| disease cornea | #131 |
| cataract phacoemulsification | #132 |
| 5ac | #132 |
| management allergic | #132 |
| eye drop | #132 |
| eyes fluorescein | #132 |
| resection severe | #132 |
| treated tacrolimus | #133 |
| gene transcription levels | #133 |
| 19 normal subjects | #133 |
| keratoplasty adult | #133 |
| skin water | #133 |
| proteins mucin | #133 |
| acrylic iol | #134 |
| pcr hla | #134 |
| normal conjunctival | #134 |
| surface examination | #134 |
| density negative | #134 |
| solutions phacoemulsification | #135 |
| specimens vivo | #135 |
| stress status | #136 |
| iop treatment | #136 |
| severity 10 | #137 |
| dry eye patients | #137 |
| eosinophil adhesion | #137 |
| antiallergic properties | #137 |
| ocular surface | #137 |
| ophthalmological dry | #137 |
| asian dust storms | #138 |
| iol groups | #138 |
| eosinophil cationic protein | #138 |
| allergic dogs | #139 |
| authors technique | #139 |
| ratio remission | #139 |
| protein ecp | #139 |
| suppressed pretreatment | #140 |
| allergic patients | #141 |
| inflammation prostaglandin | #141 |
| aminobenzoates anti | #141 |
| interleukin1 interleukin13 | #142 |
| improvements symptom | #142 |
| findings upper | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| 52 mmhg | #144 |
| determine central | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| specimens patient | #145 |
| eye syndromes | #145 |
| symptoms ocular | #145 |
| recordable | #145 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| eye clinical | #146 |
| human conjunctiva | #146 |
| fibroblasts alpha | #146 |
| underwent evaluation | #146 |
| schiff reaction | #146 |
| virus pathogen | #146 |
| hne 4 | #147 |
| required type | #147 |
| impression cytology | #147 |
| diagnosis atopic | #147 |
| 263 years | #147 |
| dscg | #147 |
| 0001 corneal | #148 |
| ulcer drug | #148 |
| increased goblet | #148 |
| dynamic visual acuity | #148 |
| fibroblasts production | #149 |
| intraocular lens iol | #149 |
| patients allergic | #149 |
| cationic protein | #149 |
| suspension based | #149 |
| quantitative evaluation | #149 |
| concentration tacrolimus | #149 |
| japan phenotype | #149 |
| pyrimidinones treatment | #150 |
| japanese cedar pollen | #150 |
| inflammatory cells | #150 |
| controls performed | #151 |
| inflammation reduction | #151 |
| tacrolimus treated | #152 |
| postoperative secondary | #152 |
| par2 reverse | #152 |
| symptoms objective | #153 |
| eyes 11 | #153 |
| artificial tears | #153 |
| 28 surgery | #153 |
| induced eotaxin | #153 |
| increased fibroblasts | #153 |
| concentrations il4 | #154 |
| grade effects | #155 |
| male mitomycin | #155 |
| inflammation ocular | #155 |
| alcon | #156 |
| chemokine expression | #156 |
| association pm25 | #156 |
| eyelids female | #156 |
| ointments skin | #157 |
| analysis prostaglandin | #157 |
| greater inflammation | #157 |
| pcr increase | #157 |
| values improved | #157 |
| inflammatory ocular | #157 |
| lipid infiltration | #157 |
| rates untreated | #157 |
| trial tacrolimus | #158 |
| acuities | #158 |
| surface status | #158 |
| japan included | #158 |
| 3 boys | #159 |
| weeks adverse | #159 |
| immunological characteristics | #159 |
| study inflammation | #160 |
| mucin 5ac | #161 |
| muc16 | #161 |
| 28 female | #161 |
| elevation study | #161 |
| thirtysix eyes | #161 |
| chemokines production | #161 |
| acid schiff | #161 |
| 326 years | #162 |
| bromobenzenes | #162 |
| male meibomian | #162 |
| surgery topical | #162 |
| distance visual acuity | #162 |
| visit 7 | #163 |
| prevalence ocular | #163 |
| efficacy tacrolimus | #163 |
| oxidative stress status | #163 |
| studied 21 | #163 |
| olopatadine | #163 |
| twentynine eyes | #163 |
| il1beta il2 | #163 |
| steroid anti | #164 |
| spt positive | #164 |
| 30ng | #164 |
| soft contact | #164 |
| 002 treatment | #164 |
| purpose reported | #164 |
| patients topical | #164 |
| production prostaglandin | #165 |
| biological dressings | #165 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| tacrolimus ointment | #167 |
| eosinophils higher | #167 |
| cytokines allergic | #167 |
| ulcers erosions | #168 |
| males 5 | #168 |
| 12 males | #169 |
| steroidal blotting | #169 |
| patients postsurgical | #169 |
| local allergic | #169 |
| eotaxin chemokine | #169 |
| seldi | #169 |
| studies tacrolimus | #169 |
| treating refractory | #169 |
| expression chemokines | #170 |
| management enzyme | #171 |
| conjunctiva conjunctival | #171 |
| status inflammation | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| vivo confocal | #174 |
| slit lamp | #174 |
| standard conventional | #174 |
| status oxidative | #174 |
| subjective symptoms | #174 |
| pcr flow | #174 |
| distance acuity | #174 |
| 34 eyes | #175 |
| postkeratoplasty | #175 |
| evaluated symptoms | #176 |
| homologous molecule | #176 |
| subbasal | #177 |
| dust extract | #177 |
| treatment corneal | #177 |
| aldehydes biomarkers | #177 |
| study longterm outcomes | #177 |
| acrysof | #178 |
| endophthalmitis female | #178 |
| tryptase | #178 |
| mild 2 | #178 |
| strabismus adolescent | #178 |
| reduction intraocular pressure | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| migration eosinophils | #180 |
| dyes follow | #180 |
| japan young adult | #180 |
| 4 female | #180 |
| ceramides child | #180 |
| compared eye | #180 |
| myopic regression | #180 |
| lipid study | #181 |
| normal control patients | #181 |
| cutometer | #181 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| serum il4 | #183 |
| male radioallergosorbent | #184 |
| human lymphocyte antigen | #185 |
| mucin4 mucins | #185 |
| igg virus | #185 |
| examined parameters | #186 |
| therapy corneal | #186 |
| nerve prospective | #186 |
| efficacy topical | #187 |
| suspensions administration | #187 |
| par2 mrna | #187 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| corneal fibroblasts | #187 |
| eye symptoms | #188 |
| corneal sensitivity | #188 |
| il13 increased | #188 |
| 19 eyes | #188 |
| seconds patients | #189 |
| allergic cross | #189 |
| sensitivity regulation | #189 |
| production stromal | #189 |
| levels 33 | #190 |
| effects diesel | #191 |
| tear break | #191 |
| infiltrating eosinophils | #191 |
| assisted infrared | #191 |
| improvement subjective | #192 |
| therapeutic study | #193 |
| allergic rhinoconjunctivitis | #193 |
| controls vivo | #193 |
| 26 eyes | #194 |
| expression rantes | #195 |
| fibroblasts inhibited | #195 |
| reactivation epstein | #195 |
| female histamine | #196 |
| rigid gas | #196 |
| 80 allergens | #197 |
| interleukin4 production | #197 |
| methods primary | #197 |
| tear film stability | #197 |
| treatment topical | #197 |
| eyes 21 | #197 |
| tears time | #198 |
| combination topical | #198 |
| 28 eyes | #198 |
| elisa performed | #198 |
| pollen prospective | #199 |
| effects topical | #199 |
| photorefractive keratectomy | #201 |
| perennial allergic | #201 |
| mcp1 ip10 | #201 |
| pollen allergic | #201 |
| preservative free | #201 |
| receptor homologous | #202 |
| hypersensitivity interleukin13 | #202 |
| unit density | #202 |
| rsv infected | #202 |
| eosinophils neutrophils | #203 |
| grade scale | #204 |
| differences iop | #204 |
| vcam1 icam1 | #204 |
| pge2 human | #204 |
| ova alum | #204 |
| inflammatory allergic | #205 |
| eyes 005 | #205 |
| minutes 8 | #206 |
| disease acd | #206 |
| eyes cataract | #206 |
| disease dry | #206 |
| time tbut | #206 |
| count cornea | #207 |
| crth2 | #207 |
| pressure lens | #207 |
| glands middle | #207 |
| ecp levels | #207 |
| formation giant | #207 |
| fluorescein fluorescent | #208 |
| mammalian milk | #208 |
| tears aged | #208 |
| size contact | #208 |
| analysis pm25 | #209 |
| uncorrected corrected | #209 |
| human allergic | #210 |
| month reduction | #210 |
| treatment allergic | #210 |
| refractory conventional | #211 |
| antiallergic drug | #211 |
| oct diagnosis | #211 |
| combination tests | #212 |
| iol patients | #212 |
| inflammation injection | #212 |
| tacrolimus combination | #212 |
| conjunctiva eye | #213 |
| treated refractory | #213 |
| chamber anti | #213 |
| steroids treatment | #214 |
| muc5ac | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| lens purpose | #218 |
| worse eyes | #218 |
| nuclear cataract | #219 |
| expressions higher | #219 |
| august october | #220 |
| conjunctival biopsy | #220 |
| tranilast | #220 |
| metabolism lysine | #220 |
| conjunctivitis acute | #221 |
| findings inflammation | #221 |
| level ambient | #222 |
| cells crth2 | #222 |
| samples correlated | #222 |
| combined therapy | #222 |
| diseases dry | #222 |
| twentyfour eyes | #222 |
| symptoms short | #224 |
| iop corneal | #224 |
| 26 control subjects | #224 |
| sensitivity measurements | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| followup cases | #229 |
| itching | #229 |
| treatment superior | #230 |
| eye signs | #230 |
| corrected distance | #230 |
| activity eosinophils | #231 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| examined level | #232 |
| events initiation | #232 |
| scleral flap | #232 |
| alpha defensin | #232 |
| proteinchip | #233 |
| 791 patients | #233 |
| dye staining | #233 |
| concomitantly administered | #233 |
| anti allergic | #233 |
| cyclosporine treatment | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| quantitatively evaluate | #236 |
| specimens patients | #236 |
| corneal disease | #236 |
| gamma transcripts | #237 |
| term topical | #237 |
| topical steroid | #238 |
| diagnostic abilities | #240 |
| tool quantitative | #240 |
| studied subjects | #240 |
| proliferative lesions | #240 |
| bf patients | #241 |
| eyes ocular | #241 |
| cromolyn sodium | #242 |
| surface lipid | #242 |
| cell chemotactic | #242 |
| performed higher | #245 |
| common ocular | #245 |
| specular microscopy | #246 |
| eye drops | #247 |
| subjects males | #247 |
| equivalent 2 | #247 |
| specificity cutoff | #248 |
| chemosis | #248 |
| failure visual | #250 |
| response prostaglandin | #251 |
| labeling intercellular | #251 |
| seasonal allergic | #252 |
| leukocyte child | #252 |
| subjective objective | #252 |
| males 13 | #252 |
| syndrome tears | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| muc | #255 |
| improved vision | #255 |
| corneal female | #255 |
| rantes expression | #256 |
| dexamethasone inhibition | #256 |
| stability positive | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| eosinophil infiltration | #260 |
| month treatment | #260 |
| additional medications | #260 |
| role histamine | #260 |
| eyes control | #260 |
| human transcription | #261 |
| expression rsv | #261 |
| h1 antagonist | #262 |
| smaller normal | #262 |
| aged mucin | #264 |
| immunohistochemistry increased | #264 |
| 1 month treatment | #264 |
| severity adverse | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| data weekly | #267 |
| signs blood | #267 |
| patients sjögren syndrome | #268 |
| treatment atopic | #268 |
| microscopy negative | #268 |
| respiratory syncytial virus | #268 |
| studied production | #268 |
| sodium drug | #269 |
| aged aldehyde | #270 |
| h1 histamine | #270 |
| computer terminals | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| improved visual acuity | #273 |
| 13 males | #273 |
| aldose reductase inhibitor | #273 |
| epithelium endothelium | #274 |
| combination eosinophils | #274 |
| concentration quantitative | #274 |
| studies stevens | #274 |
| meibomian gland dysfunction | #275 |
| tear breakup time | #277 |
| patients sjögren | #277 |
| meibomian gland | #277 |
| individuals pcr | #278 |
| tbut | #278 |
| grading score | #278 |
| 13 females | #279 |
| eyes 14 | #279 |
| bloodaqueous barrier | #279 |
| 0001 diagnosis | #279 |
| multifunctional glycoprotein | #280 |
| interleukin il4 | #280 |
| required provide | #281 |
| 10 seconds | #281 |
| disease purpose | #282 |
| expressed th2 | #282 |
| cautery | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| amniotic membrane | #285 |
| contralateral eye | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| adult alkylating | #289 |
| study tacrolimus | #289 |
| entericcoated | #291 |
| eyedrops | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| treatment 01 | #294 |
| exponential equation | #294 |
| new antifungal | #294 |
| levels ige | #295 |
| single therapy | #295 |
| serum periostin | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| severity diagnosis | #300 |
| rose bengal | #300 |
| benzalkonium chloride | #301 |
| pkp | #301 |
| morphologic alterations | #302 |
| moderate 3 | #303 |
| assessed based | #303 |
| cobblestone | #303 |
| scanning laser | #304 |
| photophobia | #304 |
| operation patient | #305 |
| scores worse | #305 |
| initiation treatment | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| membrane patch | #307 |
| assessed 4 | #307 |
| gel application | #308 |
| evaluation groups | #309 |
| interleukin13 interleukin2 | #309 |
| 10 normal subjects | #309 |
| inflammatory cell | #310 |
| comfort level | #310 |
| compared simple | #310 |
| slitlamp examination | #311 |
| regard age | #311 |
| 12 eyes | #311 |
| cytology specimens | #311 |
| treatment seasonal | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| eye adult | #315 |
| aged staining | #315 |
| child corneal | #316 |
| 19 normal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| dermatitis clinical | #320 |
| prospective singlearm study | #320 |
| fluorophotometry | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| ulcers | #323 |
| bilateral cataracts | #323 |
| pollen allergen | #324 |
| agreement weighted | #324 |
| 15 30 minutes | #325 |
| eyes 19 | #325 |
| 095 ± | #326 |
| icam1 vcam1 expression | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| pressure ocular | #331 |
| treatment 2 weeks | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| values daily | #335 |
| proprietary | #336 |
| corneal epithelial | #337 |
| male staphylococcal | #337 |
| 27 eyes | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| eyes 27 | #341 |
| levels epithelial | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| measurements treatment | #347 |
| corneal infection | #347 |
| eyes 13 | #348 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| surgery eye | #350 |
| test values | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| expression allergic | #354 |
| weekly average | #354 |
| temperature infrared | #355 |
| incidence allergic | #355 |
| examination serum | #356 |
| choroidal detachment | #356 |
| tear film | #357 |
| patients allergy | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| plant pollen | #368 |
| function laser | #368 |
| treatment ocular | #368 |
| studies sclera | #368 |
| corneae male | #369 |
| eyes 17 | #370 |
| mucin1 mucin2 | #370 |
| postoperative adhesion | #370 |
| systemic control | #371 |
| inhibitors epithelium | #372 |
| cryptomeria japonica | #372 |
| sixteen eyes | #373 |
| micafungin middle | #374 |
| periodic acid schiff | #374 |
| cornea female | #375 |
| assessment severe | #375 |
| improvement local | #375 |
| retina tomograph | #376 |
| extraction cell | #376 |
| 4 lower | #377 |
| 10 normal | #377 |
| higher human | #377 |
| levels atopic | #377 |
| phacoemulsification prospective | #377 |
| count child | #378 |
| tarsal | #378 |
| treatment eyes | #378 |
| mitomycin | #380 |
| stimulation tnf | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| pollinosis | #383 |
| inflammation epithelial | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| limit assay | #388 |
| surface alterations | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| severity incidence | #390 |
| sde | #390 |
| patients proteins | #391 |
| antiallergic | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| chronic ocular | #395 |
| applied 5 | #395 |
| relative percentages | #396 |
| techniques interleukin4 | #396 |
| opacity corneal | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| declaration helsinki | #400 |
| remission based | #400 |
| eyes severe | #401 |
| modified boyden | #401 |
| rays male | #402 |
| sedating humans | #403 |
| weather air | #404 |
| vogt | #404 |
| measurements oct | #404 |
| cells allergic | #404 |
| prospective controlled study | #405 |
| reproducibility surface | #406 |
| patients epithelial | #406 |
| improved diagnosis | #407 |
| 137 years | #407 |
| serum total ige | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| confocal | #412 |
| acids fibroblasts | #412 |
| specific total | #412 |
| eyes 15 | #412 |
| counts 1 | #413 |
| allergic reaction | #413 |
| 3 months treatment | #413 |
| keratocytes | #414 |
| limbal | #416 |
| postoperative inflammation | #416 |
| penetrating keratoplasty | #418 |
| central cornea | #418 |
| mucin4 | #419 |
| speed resolution | #419 |
| chemokine ccl11 | #419 |
| patients comfort | #419 |
| ophthalmologist | #420 |
| sjögren syndrome | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| clinical observation | #425 |
| 40 minutes | #425 |
| trabeculectomy visual | #430 |
| production 4 | #430 |
| rhinoconjunctivitis | #431 |
| staining score | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| performed immunohistochemistry | #437 |
| cedrus | #437 |
| regulation eye | #438 |
| 5 women | #438 |
| methods eye | #438 |
| commercial tests | #439 |
| foldable | #440 |
| subjects studied | #440 |
| interleukin4 il4 | #440 |
| fluorescein dye | #441 |
| regulation chemokine | #441 |
| landolt | #441 |
| vmr | #441 |
| adult aldehydes | #442 |
| anti vcam1 | #442 |
| females normal | #442 |
| male mucin1 | #444 |
| 17 males | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| dogs dust | #448 |
| air pollution data | #448 |
| 30 serum | #450 |
| male 4 | #450 |
| eye eyes | #451 |
| wash | #452 |
| keratoplasty | #452 |
| ketotifen | #453 |
| versus vehicle | #453 |
| antagonists sedating | #453 |
| vivo confocal microscopy | #454 |
| normal patients | #454 |
| response allergens | #454 |
| surface disorder | #454 |
| water evaporation | #455 |
| production clearance | #455 |
| ophthalmic nerve | #455 |
| 8 genes | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| amnion cell | #457 |
| ocular risk | #457 |
| normal controls patients | #457 |
| outpatient visits | #457 |
| checker | #459 |
| oct study | #460 |
| distance visual | #461 |
| greatest improvements | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| background atopic | #469 |
| examination diagnosis | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| diagnosis rate | #476 |
| hladr expression | #476 |
| fibroblasts primary | #478 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| newly formed vessels | #480 |
| height measurement | #480 |
| reduce clinical | #480 |
| subjects eyes | #481 |
| interleukin 13 | #482 |
| examined prospective | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| myopia photorefractive | #490 |
| shortterm study | #490 |
| disodium cromoglycate | #493 |
| acuity intraocular | #495 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| corneal | #498 |
| months eyes | #498 |
| stain positive | #499 |
| il2 tumor | #499 |
| exposure diesel | #499 |
| lens iol | #500 |
| silicone hydrogel | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| pge2 cox2 | #502 |
| studies status | #502 |
| treatment eye | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| eye position | #505 |
| 2 daily | #505 |
| inflammatory status | #506 |
| airborne particulate matter | #506 |
| correlate severity | #506 |
| penetrating male | #507 |
| induced ocular | #509 |
| aldose reductase | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| topical | #516 |
| 45 subjects | #516 |
| disposable equipment | #517 |
| observed baseline | #519 |
| male water | #519 |
| inhibition production | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| 01 | #522 |
| chemoattractant receptor | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| studies trabeculectomy | #525 |
| dinoprostone epithelial | #525 |
| trabeculectomy | #527 |
| studies cornea | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| itchy | #531 |
| rhodanine | #531 |
| serum antigen | #535 |
| ocular symptoms | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| patients cataract | #538 |
| total hydrocarbons | #538 |
| sac | #539 |
| dependent migration | #539 |
| placebo tablets | #540 |
| capsular bag | #540 |
| visit 6 | #541 |
| 80 anterior | #541 |
| administration topical | #542 |
| cases flow | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| film layer | #550 |
| prospective comparative study | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| disease complicated | #553 |
| effects cooling | #553 |
| engorgement | #554 |
| disease ded | #555 |
| genechip | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| methods thirty | #559 |
| diesel exhaust particles | #559 |
| differentiation inflammatory | #560 |
| eyes iop | #560 |
| ocular infections | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| count corneal | #569 |
| 16 age | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| 4 mrna | #580 |
| iop eyes | #580 |
| apparatus male | #582 |
| fibrosis fluorescent | #582 |
| lesions normal | #582 |
| increase vegf | #584 |
| tnfalpha stimulation | #584 |
| department ophthalmology | #584 |
| symptoms scores | #588 |
| induced 4 | #589 |
| corneal epithelium | #589 |
| female humans allergic | #589 |
| hladr antigen | #589 |
| intraocular male | #589 |
| patients csa | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| topical adult | #609 |
| inflammation status | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| antagonists humans | #615 |
| patients complained | #615 |
| cells oligopeptides | #616 |
| diagnosis type | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| lamp examination | #625 |
| years studied | #625 |
| glaucoma medications | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| corneal haze | #636 |
| redness | #636 |
| patients tacrolimus | #636 |
| burning sensation | #636 |
| total immunoglobulin | #638 |
| based severity | #639 |
| eosinophils | #639 |
| contact lenses | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| 11 eyes | #641 |
| development allergic | #641 |
| months 01 | #643 |
| performed modified | #643 |
| symptoms signs | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| viscosupplements | #651 |
| 2 females | #651 |
| expression administration | #651 |
| eosinophils flow | #654 |
| analysis existence | #654 |
| diseases methods | #656 |
| comfortable | #657 |
| lacrimal | #657 |
| patients elisa | #660 |
| 96well plate | #661 |
| nerve density | #661 |
| chamber technique | #662 |
| lens wearers | #664 |
| treatment 0001 | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| damage scores | #669 |
| viruses acute | #669 |
| 10 age | #669 |
| stimulation rna | #672 |
| cedar | #672 |
| 11 males | #673 |
| humans lacrimal | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| adherence anti | #681 |
| test methods | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| cells eye | #694 |
| atopic female humans | #694 |
| 1 test | #695 |
| early antigen | #697 |
| inhibition expression | #697 |
| objective assessments | #700 |
| levels detection | #700 |
| cromolyn | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| fibroblasts flow | #715 |
| 1 month | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 32 eyes | #724 |
| 088 ± | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| aged ophthalmology | #730 |
| 11 male | #730 |
| followup treatment | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| keratectomy | #741 |
| density compared | #741 |
| expression real | #744 |
| unpaired test | #746 |
| definition classification | #746 |
| blood eosinophils | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| follow cases | #759 |
| iol implantation | #759 |
| allergens anti | #762 |
| intraocular lens implantation | #763 |
| trabeculectomy treatment | #763 |
| topical aged | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| pathogenesis severe | #769 |
| oligopeptides rna | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| fluorescein fluoresceins | #784 |
| limbus corneae | #784 |
| treatment 1 | #785 |
| purpose analyze | #785 |
| blinking | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| eyes normal | #792 |
| lenses intraocular | #792 |
| tacrolimus | #793 |
| techniques laminin | #793 |
| increased epithelial | #793 |
| 4 hne | #794 |
| ocular inflammation | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| positive linear | #801 |
| report efficacy | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| mucin | #813 |
| receptors ccr3 | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| lymphocytes compared | #834 |
| preoperative level | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| individuals patients | #841 |
| patients operation | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| new surgical technique | #845 |
| elevated iop | #845 |
| levels air | #848 |
| exhaust | #848 |
| 2 weeks treatment | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| inhibitors diclofenac | #861 |
| myopic eyes | #861 |
| thiazolidines | #865 |
| histamine h1 | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| 01 compared | #874 |
| patients eyes | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| benzamidine | #880 |
| h1 antagonists | #880 |
| evaluation early | #880 |
| patient comfort | #881 |
| cells contributes | #882 |
| assessing efficacy | #882 |
| diseases background | #883 |
| study eye | #886 |
| bleb | #887 |
| patients condition | #887 |
| specular | #890 |
| 114 years | #894 |
| respiratory syncytial | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| 8 males | #928 |
| treatment symptoms | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| ophthalmologic surgical | #933 |
| normal controls | #933 |
| epithelialization | #937 |
| beta1 tumor | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| symptoms evaluated | #941 |
| cytokines epithelial | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| scanning confocal | #957 |
| 2 moderate | #957 |
| singleagent therapy | #959 |
| aldose | #959 |
| 3 eyes | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| tenon | #994 |
| observed conclusions | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| methods sixteen | #1002 |
| observed vivo | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| 045 ± | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| disposable | #1067 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| noninfectious | #1070 |
| goblet cell | #1071 |
| acuity patients | #1071 |
| immunocytochemical study | #1073 |
| effective treating | #1075 |
| months corrected | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| ade | #1080 |
| syncytial virus | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| diseases objective | #1104 |
| assessed vivo | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| drops | #1121 |
| keratopathy | #1121 |
| 92 years | #1122 |
| popularization | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| assay fibroblasts | #1133 |
| clinical findings | #1133 |
| treatment objective | #1133 |
| cultures human | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| visual acuities | #1140 |
| healthy eyes | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| 4 daily | #1146 |
| p0035 | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| purpose evaluate | #1171 |
| sjögrens syndrome | #1171 |
| glands sjogren | #1173 |
| cornea | #1173 |
| ophthalmological female | #1189 |
| immune mechanisms | #1189 |
| fibronectins fibrosis | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| concentrations alpha | #1210 |
| 84 ± | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| higher severe | #1316 |
| chemokines chemotaxis | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| expressed secreted | #1321 |
| child chromatography | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| 18 eyes | #1399 |
| female glucocorticoids | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| goblet cells | #1451 |
| reduced 1 | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| female fluorescein | #1514 |
| staining | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| vdt | #1624 |
| humans intraocular | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| 10 healthy controls | #1663 |
| syncytial | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| disease defined | #1713 |
| outcome visual | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| cytology | #1741 |
| central corneal | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| receptor par2 | #1823 |
| japan methods | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| 15 minutes | #1828 |
| eosinophil | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| shield | #1860 |
| comparative evaluation | #1860 |
| tnfalpha production | #1862 |
| ari | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| aphakia | #1893 |
| cataract surgery | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| protein female | #1946 |
| severe persistent | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| versus normal | #2067 |
| ambient air pollution | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| endopeptidases serine | #2137 |
| docosahexaenoic acid | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| curve reproducibility | #2164 |
| production inhibited | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| diseases female | #2192 |
| aged mitomycin | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| pollens | #2247 |
| scores correlated | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| ophthalmology | #2415 |
| aged nitrogen | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| fungal female | #2498 |
| enteric coated | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| methods clinical | #2571 |
| oct | #2571 |
| male polymerase | #2573 |
| flare | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| postsurgical | #2629 |
| eosinophilia female | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| test performed | #2907 |
| anterior chamber | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| measured elisa | #3014 |
| eosinophils humans | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| vegf mrna | #3694 |
| disease adolescent | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| management disease | #3773 |
| helper type | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| chemokines | #3992 |
| microscopy | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| papillary | #4193 |
| α induced | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| months treatment | #5023 |
| nitrogen dioxide | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| epithelium | #5224 |
| thirtysix patients | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| th2 cells | #5747 |
| grades | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| house dust | #6543 |
| rejection humans | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| glucocorticoids humans | #6618 |
| linked immunosorbent | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| complaints | #9098 |
| 3 6 | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| alkylating | #18391 |
| stained | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
运行报告 | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| 闻名 Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| 闻名 Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| 闻名 Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| 闻名 Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| 闻名 Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| 闻名 Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| 闻名 Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| 闻名 Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| 闻名 Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| 闻名 Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| 闻名 Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| 闻名 Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| 闻名 Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| 闻名 Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
关键人物 Allergic Conjunctivitis
世界顶级科尔斯
Hiroshi Fujishima:专家影响
哪个概念Hiroshi Fujishima具有直接影响:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:KOL的影响
与其他作者的工作有关的概念for which Hiroshi Fujishima 有影响力:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
这是您的个人资料吗？ 要求您的个人资料 复制URL 嵌入到您的个人资料的链接 |